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A STUDY OF EXPRESSION OF EPIDERMAL GROWTH FACTOR 
RECEPTOR(EGFR) AND VASCULAR ENDOTHELIAL GROWTH 
FACTOR (VEGF) IN EPITHELIAL OVARIAN NEOPLASMS 
 
ABSTRACT 
INTRODUCTION 
Ovarian carcinoma is the 6th most common carcinoma among women in 
the world  and forms 1.7 to 8.7% of female cancers in India.It is the most 
common cause of gynecological cancer death in women. Surface epithelial 
ovarian carcinoma accounts for 90 to 95% of ovarian malignancies. 
 
EGFR (Epidermal Growth Factor Receptor) 
 Among various prognostic indicators, EGFR  a 170 Kd  glycoprotein 
maintained its independent prognostic value,and brings about increased DNA 
synthesis, cell proliferation  and differentiation. With the availability of EGFR –
inhibitors, selection of patients for EGFR – targeted therapy becomes more 
important. 
 
VEGF (Vascular Endothelial Growth Factor) 
 VEGF is a dimeric glycoprotein  functioning as a tumour angiogenesis 
factor. 
 Bevacizumab – Anti VEGF, antibody shows promise in the treatment of 
ovarian cancer.  
 
This study is an attempt to determine the expression of the above two 
markers -EGFR and VEGF  in epithelial ovarian neoplasms. 
 
AIMS AND OBJECTIVES:  
 To study the expression of EGFR (Epidermal Growth Factor Receptor) 
and VEGF (Vascular Endothelial Growth Factor) in epithelial ovarian 
neoplasms, which could thence be, used as therapeutic targets in future. 
 
MATERIALS AND METHODS:  
 30 cases paraffin sections of ovarian specimen diagnosed as borderline 
and malignant epithelial ovarian neoplasms were subjected to staining with 
ImmunoHistoChemical  markers-EGFR and VEGF. 
 
RESULTS:  
 Out of 4 borderline ovarian neoplasms, 50% showed positivity for EGFR 
while 75% of them showed positivity for VEGF. 
 
 Among malignancies, 80.76% of them showed EGFR positivity while 
84.02%  showed VEGF positivity.  
 
CONCLUSION:  
 With Immunohistochemical analysis, the percentage of EGFR and VEGF 
expression showed a significant increase in malignant compared to borderline 
tumours. Even among malignancies, EGFR and VEGF showed a significant 
correlation with tumour grade and FIGO stage. High grade and advanced stage 
tumours showed EGFR and VEGF overexpression compared to low grade and 
early stage carcinomas. 
 
KEYWORDS: 
 Surface epithelial ovarian carcinoma, EGFR, VEGF, 
Immunohistochemical analysis, Bevacizumab. 
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INTRODUCTION 
 
 Ovarian carcinoma is the 6th most common carcinoma among women in 
the world [1] and  it ranks fifth  in cancer deaths among women.  [2]. Surface 
epithelial ovarian carcinoma accounts for 90 to 95% of ovarian malignancies [3] 
 
 Surface epithelial tumours, statistically the most important group of 
neoplasms are derived from surface coelomic or germinal epithelium that is 
continuous with the mesothelium that covers the peritoneal cavity, sharing with 
it a common origin and many morphological features. The ovarian surface 
epithelium involved in metaplastic or neoplastic conditions often undergo 
‘mullerian differentiation’ and may produce any of the adult structures formed 
by the mullerian ducts including tubal, endometrial and endocervical mucosa, 
singly or in combination [5]. It has also been noted  that many of  the surface 
epithelial tumors arise from the invaginated portion of the epithelium that 
forms  surface epithelial glands and cysts [6]. Another proposed origin of some 
ovarian epithelial tumours (especially serous type) is the epithelium of the tubal 
fimbriae and fimbriae are the most common sites of early serous carcinoma in 
women with BRAC mutations [7].  
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 The parameters based on which the surface epithelial ovarian tumors are 
classified are: 
 
1. Cell histological  type: Serous, mucinous, endometroid etc 
2. Growth pattern: cystic, solid etc 
3. Proportion of fibrous stroma. 
4. Degree of atypia and invasiveness: benign, borderline and malignant [6] 
 
 A new model divides surface epithelial tumours into 2 major  categories: 
Type 1 and Type 2, based on their clinicopathological features and 
characteristic molecular genetic changes [8]. 
 
 Type 1 tumors are slow growing, generally confined to the ovary at the 
time of diagnosis and developing from well-established precursor lesions [9]. 
 
 Type 2 tumors are rapidly growing, highly aggressive neoplasms for 
which well-defined precursor lesions have not been identified. More than 75% 
of them have TP53 mutations [10].  
 
ROLE OF BIOMARKERS:  
 Ovarian carcinoma is comparatively asymptomatic in early stage and is 
aptly called a “silent killer disease”.70% of patients present in stage III and IV  
underscoring the  need for early biomarkers since the survival rates vary 
significantly with the stage at diagnosis. 
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TABLE 1:    5 YEAR SURVIVAL RATES FOR EPITHELIAL 
OVARIAN CANCERS: 
STAGE OF THE EPITHELIAL OVARIAN 
CARCINOMA 
5 YEAR SURVIVAL 
RATE 
STAGE  I 90% 
STAGE  II 70% 
STAGE   III 39% 
STAGE   IV 17% 
 
“Survival rate for ovarian cancer by stage”- AMERICAN CANCER 
SOCIETY-retrieved on 29 oct 2014. 
 
BIOMARKERS IN DIAGNOSIS: 
 The long used CA-125 is raised in only 50% of  early stage ovarian 
cancers [11]. It is also highly non-specific. The need of the hour are other 
complimentary biomarkers in early diagnosis and prognostication. Two amidst 
these novel biomarkers are EGFR (Epidermal Growth Factor Receptor) and 
VEGF (Vascular Endothelial Growth Factor).A multivariate cox analysis 
regression model showed that high serum VEGF expression in stage I patients 
is correlated  with 8 fold increase in cancer mortality[12].Compared to benign 
ovarian lesions,early stage ovarian cancer patients showed raised levels of 
VEGF.Hence when used in combination with CA-125,the sensitivity was 
increased upto 96% and specificity up to 77%.[13] 
 
BIOMARKERS IN PROGNOSTICATION: 
 Higher levels of EGFR and VEGF are associated with metastases, 
development of ascites and poorer prognosis. 
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BIOMARKERS IN THERAPEUTICS: 
 It has been predicted that simultaneous inhibition of 2 key tumor 
dependent growth factor pathways EGFR and VEGF, causes Receptor Tyrosine 
Kinase (RTK) pathway disruption and consequently tumor growth 
arrest/inhibition. [13] 
 
EGFR (Epidermal Growth Factor Receptor) 
 Among various prognostic indicators, EGFR maintained its independent 
prognostic value. EGFR is a 170KD transmembrane glycoprotein. Ligand 
binding triggers intrinsic tyrosine kinase activity of the receptor activating 
numerous cellular responses like increased DNA synthesis, cell proliferation 
and cell differentiation. With the availability of EGFR inhibitors, selection of 
patients for EGFR – targeted therapy becomes more important. 
 
VEGF (Vascular Endothelial Growth Factor) 
 The dimeric glycoprotein VEGF is structurally similar to platelet 
derived growth factor and may function as a tumour angiogenesis factor. 
Bevacizumab – anti VEGF, antibody shows promise in the treatment of ovarian 
cancer. VEGF has been known to have crucial role in neovascular formation in 
tumors, providing nourishment for the highly metabolic tumor cells and 
providing access to the host vasculature [12, 13]. 
 
 
 
Aims and Objectives 
  
5 
 
 
 
 
AIMS AND OBJECTIVES 
 
 
1. To study the expression of EGFR (Epidermal Growth Factor Receptor) 
and VEGF (Vascular Endothelial Growth Factor) in epithelial ovarian 
neoplasms, which could thence be, used as therapeutic targets in future. 
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
NORMAL ANATOMY AND HISTOLOGY 
 The ovaries are a pair of  female reproductive organs ,lying in the pelvis  
on either side of the uterus close to lateral pelvic wall, behind broad ligament 
and anterior to rectum. The mesovarium attaches it to posterior aspect of broad 
ligament along its anterior margin. The ovarian ligament attaches it to the 
ipsilateral uterine cornua and infundibulopelvic ligament attaches it to the 
lateral pelvic wall [14]. Adult ovary has an ovoid shape and measures (3 to 5 
cm) x (1.5 to 3 cm) x (0.6-1.5 cm) and weighs 5 to 8 grams during the 
reproductive period. After menopause, they shrink to one half of this size [15] 
 
LYMPHATICS 
 The majority of the ovarian  lymph vessels drain to large trunks that 
form a plexus at the hilus and finally drain into Para aortic nodes. Few of them 
also drain into internal and external iliac, common iliac and inguinal nodes [16] 
 
BLOOD VESSELS 
 The ovarian artery, a direct branch of the aorta, courses along the 
infundibulopelvic ligament, anastomoses with the ovarian branch of uterine 
artery and forms an arcade from which about 10 arterial branches arise and 
penetrate the ovarian hilus and medulla. These form a plexus at the cortico 
medullary junction from which the radial cortical arterioles arise [15]. The veins 
accompany the arteries and finally drain into the ovarian veins. The left ovarian 
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vein drains into the left renal vein and the right ovarian vein drains into the 
inferior vena cava [18] 
 
NERVE SUPPLY 
 Nerve supply to the ovaries is through ovarian, hypogastric and aortic 
plexuses. 
 
HISTOLOGY 
 A single layer of cuboidal cells that constitute the germinal epithelium 
covers the ovarian free surface. The ovarian substance is divisible into cortex 
and medulla. Immediately deep to the germinal epithelium, the cortex is 
covered by a condensed connective tissue called the tunica albuginea, which is 
much thinner and less dense than that of testis. Deep to this, the ovarian stroma 
is made of slender spindle shaped cells, fine collagen fibres and ground 
substance. Scattered in this stroma are ovarian follicles at various stages of 
development – each containing a developing ovum. 
 
 The inner medulla consists of connective tissue in which numerous 
blood vessels are seen.It also contains elastic fibres and some smooth muscle 
fibres. The ovarian hilus cells are similar to the interstitial cells of the testis. 
 
OOGENESIS 
 Oogonia are the stem cells from which ova are derived. An oogonium 
enlarges to form a primary oocyte with diploid number of chromosomes. It 
undergoes first meiotic division to form two daughter cells with haploid 
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number of chromosomes. However the cytoplasm is not equally divided and 
most of it goes to one daughter cell which is large. The second daughter cell 
with hardly any cytoplasm forms the first polar body. The secondary oocyte 
undergoes second meiotic division to give rise 2 unequal cells – the larger one 
is the mature ovum and the smaller one is the second polar body. 
 
FORMATION OF OVARIAN FOLLICLES 
 The ovum with the surrounding flat stromal cells forms a primordial 
follicle. These form majority of follicles in the ovary. The flat stromal cells or 
the follicular cells become columnar and form the primary follicle. The 
follicular cells proliferate to form several layers of granulosa cells. The 
homogenous membrane – the ‘zona pellucida’ appears between the follicular 
cells and the developing ovum. This is a ‘secondary follicle’. A follicular 
cavity – the antrum appears, filled with a fluid – the liquor folliculi. The oocyte 
lies eccentrically in the follicle surrounded by some granulosa cells, the 
cumulus oophorus. As the follicle expands – the stromal cells surrounding the 
granulosa become condensed to form a covering called “theca interna” outside 
which some fibrous tissue becomes condensed to form another covering for the 
follicle – “the theca externa”. The first meiotic division is completed just 
before ovulation to form the secondary oocyte. Follicular antrum enlarges 
markedly. The follicle reaches the size of 1.5 cm to 2.5 cm and bulges under 
the ovarian surface as the mature ‘Graafian follicle’ 
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CORPUS LUTEUM 
 When the graafian follicle ruptures, it collapses and becomes folded and 
fills with blood. The granulous cells are enlarged with abundant pale cytoplasm 
and round nuclei, abundant smooth endoplasmic reticulum and mitochondria 
and numerous lipid droplets giving a yellow tinge and hence the name“corpus 
luteum” which secretes progesterone. 
 
EMBRYOLOGY 
OVARY 
 Formed essentially from the gonadal ridge. 
 
OVA 
 In early embryonic phase, the primordial germ cells are formed from the 
dorsal endoderm of the yolk sac and migrate along the hindgut to the gonadal 
ridge [24]. 
 
DESCENT OF THE OVARIES 
 From the lumbar region, ovaries descend to the pelvic cavity by the pull 
of gubernaculum ovarii which stretches from ovary to the skin of labium 
majus. Their descent is arrested at the pelvis by the developing uterus and the 
broad ligament. 
FUNCTIONS OF THE OVARY 
1. Gamete production associated with periodical release of ova. 
2. Endocrine functions – Ovaries secrete estrogen, progesterone and small 
amount of testosterone [21, 22] 
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TUMOURS 
WHO classification of Ovarian tumours given under Annexure 1 
 
SURFACE EPITHELIAL TUMORS 
Form two-thirds of all ovarian neoplasms [23]. They are further classified 
according to the following parameters 
a. Histological Cell type – serous, mucinous, endometrioid etc 
b. Growth pattern – cystic, solid etc 
c. Proportion of fibrous stroma. 
d. Degree of atypia and invasiness – benign, borderline and malignant 
 
EPIDEMIOLOGY 
 In western countries, ovarian carcinoma is the most common cause of 
gynaecological cancer death. It constitutes 4% of total carcinomas in women 
[93]. The approximate risk of  American women developing ovarian carcinoma 
in their lifetime is 1.4%. Generally, we can say that the disease is seen more 
commonly in industrialized western countries because of their low parity, an 
important exception being Japan, because though the parity is lower, they have 
relatively lower incidence of ovarian carcinoma.On the other hand, 
Scandinavia shows one of the highest annual incidence rates of more than 16 
per 1 lakh females [94] 
 
 The incidence of ovarian carcinoma in India, ranged from 1.7% to 8.7% 
of all female cancers as per the data gathered from urban and rural registries, 
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working under the network of National Cancer Registry Programme (NCRP) of 
ICMR (Indian Council of Medical Research) [107]. The total number of new 
cancer patients in India is well on the rise partly due to the increase in 
population and also due to the relative rise in the  proportion of elderly 
population due to improved  life expectancy. Ovarian carcinoma ranks 
third/fourth among the cancers occurring in women in India. In the national 
cancer  registries from Ahmedabad / Bengaluru and Chennai, an increase in the 
mean annual percentage change was noted in age group of 55-64 years [108]. 
Lifestyle changes towards industrialization and urbanization in India , 
especially  rise in age at marriage, delay in age at first birth, reduced parity, 
increase in incidence of obesity, diabetes, hypertension, cancer corpus  uterus-, 
diet rich in saturated/animal fats have all contributed to the increased incidence 
of ovarian carcinoma in India. Maximum increase over the last 10 year period 
was observed in Nagpur with the mean annual percentage increase of 2.4%. 
Some of this increase is also attributed to improved certification and 
registration of the disease in the recent years. 
 
 In the  recent years, one significant change noted is that there is a 
relative fall in the incidence of ovarian carcinoma, as tubal carcinoma and 
peritoneal carcinomas have started showing an increasing trend [95] 
 
 Migration studies show that, the rate of ovarian carcinoma is determined 
by the immigration place rather than the emigration place - indicating a 
significant environmental component in the risk of ovarian carcinoma. 
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 The incidence of ovarian carcinoma also shows a distinct variation 
according to the ethnicity. White women have increased incidence compared to 
African-American and Asians. Asian women have a 48% lower death rate 
compared to that of white women. Jews have eight times increased risk of 
developing ovarian carcinoma compared to non-Jewish women because 1 in 40 
of them have a BRCA1 mutation [96] 
 
ETIOLOGY AND RISK FACTORS 
1. Age: Risk increases with age. Mean age in India is 40-59 years. The 
average age of women affected in hereditary syndromes (like Lynch 
syndrome) is much lower than others. 
2. Reproductive factors: Early menarche and late menopause are 
significant risk factors. Increase in number of pregnancies and consistent 
oral contraceptive pill usage are proved to be protective against ovarian 
carcinoma. Increase in number of pregnancies appear to be relatively 
more protective against endometroid and clear cell carcinoma subtypes.  
3. Ovulation and Hormonal factors: “Incessant ovulation” predisposes to 
malignant transformation of the actively proliferating surface 
epithelium. The occurrence of ovarian carcinoma is directly linked to the 
total duration of reproductive years without interruption by pregnancies 
(or) oral contraceptive pill usage. Recent studies support the fact that 
consistent oral contraceptive pill usage reduces the risk of ovarian 
cancer by 50%. The protective effect becomes stronger with longer 
13 
 
duration of usage. Another theory says that increased levels of 
circulating gonadotrophins increases the chance of incidence of ovarian 
cancer either directly (or) by increasing the circulating levels of 
oestrogen. Another theory proposes that the levels of androgens are also 
important in the causation of ovarian carcinoma. 
4. Inflammation: High grade serous carcinomas are associated with 
chronic salpingitis in 53% of cases [24] 
5. Others: Include Body Mass Index, diet, talc, smoking, ionizing 
radiation, surface epithelial dysplasia, surface epithelial inclusions, 
endometriosis, serous tubal intraepithelial carcinoma. Other important 
protective factors include hysterectomy, fallopian tube ligation, and 
bilateral salpingo – oophorectomy, -the protective mechanism being 
prevention of retrograde passage of endometrial tissue and, 
endometriosis. Hence the incidence of clear cell carcinoma varies 
inversely with tubal ligation [97] 
6. Genetic Factors: At least 10% of ovarian carcinomas arise in the setting 
of highly penetrant, autosomal dominant genetic predisposition. These 
include BRCA1 and BRCA2, HNPCC (Hereditary Nonpolyposis 
Colorectal Cancer Syndrome), Lynch syndrome [25] 
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CLINICAL FEATURES 
 The patient often presents with vague, nonspecific symptoms like 
bloating, abdominal distension, dyspepsia, lower abdominal pain, loss of 
appetite and loss of weight, nausea, vomiting, increased frequency and urgency 
to urinate [26]. 
 
PROBABLE HISTOPATHOLOGICAL PRECURSOR LESIONS 
1. Surface epithelial Dysplasia 
 Recent investigations indicate that subtle nuclear changes were seen in 
ovaries removed prophylactically from high risk women compared to normal 
controls [98].  
 
2. Surface epithelial inclusions 
 Several studies have shown that ovaries of prophylactic oophorectomy 
specimens from high risk women showed invaginations of cortical epithelium 
(clefts) and papillomatosis more commonly than in controls. 
 
3. Endometriosis 
 The best studied and most easily recognized precursor lesion is 
“endometriosis”. Endometriosis is a common lesion found in about 10% of 
reproductive age women. A series of studies support the fact that endometriosis 
was at least as common as serous cystadenoma and hence would be the most 
common benign ovarian lesion.  
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 Extensive studies also show that the incidence of carcinoma in a known 
case of endometriosis is just 0.3 to 3% [99]. In a Sweden based study of more 
than 20,000 hospitalized women with endometriosis, a 11.4 year follow-up 
showed that the relative risk of carcinoma in ovarian endometriosis is 1.9. The 
mean age of occurrence of carcinoma in these cases was 51 – showing that the 
incidence of carcinoma in endometriosis occurs in a relatively younger age 
group. 
 
4. Benign and atypical proliferating neoplasms 
 Molecular analysis studies, strongly suggest that borderline tumours are 
forerunner lesions of low grade serous, endometroid and mucinous carcinomas. 
 
5. Serous Tubal Intraepithelial carcinoma (STIC) and p53 signature 
 There is a recent proposal that fallopian tubal fimbriae are the origin of 
some of serous carcinomas. Serous tubal Intraepithelial Carcinomas (STICs) 
have been found to be associated with greater proportion of high grade serous 
carcinomas [100]. These STIC lesions harbour TP53 mutations. Though they 
are cytologically malignant lesions, they are confined to the tubal epithelium. A 
minimum of 12, p53 positive, fallopian tubal secretory epithelial cells define a 
case of “p53 signature”. This p53 signature being a candidate for STIC 
precursor. 
 
 The junctions between different types of epithelium have long been 
known as “Hot Spots” for origin of carcinomas. Similarly, Tubal-Peritoneal 
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junction (TPJ) or the meeting zone of peritoneum with fimbrial epithelium has 
been evaluated as the source of serous carcinomas. 
 
PREVENTION 
 A study involving more than 80,000 women has shown that there exists 
an inverse relation between caffeine intake and ovarian carcinoma risk. 
Smoking has been found to increase the risk of mucinous carcinoma.Avoidance 
of smoking and all other possible risk factors may play a role in prevention, to 
a certain extent. 
 
STAGE AND PATTERN OF SPREAD 
 Grading and FIGO staging of ovarian carcinoma has been given in the 
annexure.  
 
 FIGO stage appears to be the most powerful predictor  of outcome in 
ovarian carcinoma compared to most other prognostic factors. Histological type 
of ovarian carcinoma determines the stage of presentation. Most of the 
mucinous subtypes presented in stage I while only about 3% of serous 
carcinomas presented in stage I. A series of numerous studies show that only 
14% of ovarian carcinomas presented in stage I. Most common presentation of 
carcinoma ovary is in stage III and 84% of stage III carcinomas were stage III 
C, involving spread to the abdominal (or) extra pelvic peritoneum [101]. Two 
thirds of cases of ovarian carcinoma show presence of ascites. 
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 The incidence of lymph node metastasis varies with the stage. Stage I 
tumours show lymph node metastasis in about 9% of cases, stage II – 36%, 
stage III 55%, and stage IV tumours show lymph node metastasis in about 88% 
of cases. Volume of residual disease forms an important prognostic factor for 
stage III and IV carcinomas. 
 
 Stage IV tumours include those showing distant metastasis and includes 
patients with liver parenchymal metastasis and extra abdominal metastasis. 
Lung and pleural metastasis are seen in up to 45% of patients with ovarian 
carcinoma, one of the most common causes of death among ovarian carcinoma 
patients being respiratory failure. Metastasis to liver- seen in up to 50% of 
ovarian carcinoma patients at autopsy. The average period of survival of 
patients with liver metastasis is about 1 year. Skin and subcutis of periumblical 
region have been the most frequent site of anterior abdominal wall metastasis. 
Only 0.1% of patients show brain metastasis at presentation. 1-2% of patients 
develop bone metastasis during the disease course. 
 
SEROUS TUMORS 
 Constitute one fourth of all ovarian tumors of which 30% to 50% are 
bilateral, 75% are benign or borderline while 25% of these are malignant [27]. 
The serous cystadenocarcinomas are the most common of all malignant ovarian 
tumors. Common age group affected is between 20 to 50 years [22]. Grossly 
they are solid and cystic with often papillary excrescences, areas of 
haemorrhage and necrosis. Microscopically the cystic areas are formed by tall 
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columnar cells and filled with clear serous fluid. Borderline tumors may have 
cellular atypia and stratification but there is no evidence of invasion. 
‘Psammoma bodies’ if present are pathognomonic of papillary serous 
cystadenocarcinomas. Micropapillary serous carcinomas are characterized by a  
pattern of highly complex micropapillae arising from large bulbous papillary 
structures and are characterized by higher rates of recurrence. 
Immunohistochemically, they are typically, CK7, WT1 and  CA125 positive. 
The 5 year survival rate of borderline and malignant tumors are 90% and 25% 
respectively. 
 
MUCINOUS TUMORS 
 These are less common and are bilateral in only 10-20% of cases [29]. 
Microscopically divided into 2 major types the intestinal type wherein the 
epithelial lining shows ‘picket fence’ appearance, goblet cells, paneth cells etc 
[30]. The endocervical or the mullerian type shows endocervical type lining 
epithelium [31]. Stromal invasion differentiates borderline from malignant 
tumors. 10 year survival rate for borderline and malignant mucinous tumors are 
90% and 65% respectively. IHC – positive for CDX2, CEA, CK20, CA125 
etc.[32] 
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ENDOMETRIOID TUMORS 
 Comprise 10-25% of all primary ovarian carcinomas. Endometriotic 
findings noted in 10 to 20% of cases [33]. 15 to 30% of cases show concomitant 
endometrial hyperplasia or carcinoma. Microscopically made of endometrial 
tubular glands. 40% of these tumors are bilateral tumors. Borderline tumors 
have a complex branching pattern without stromal invasion. 5 year survival rate 
for tumors confined to the ovary is 75%. 
 
CLEAR CELL TUMORS 
 Microscopically grow in tubulocystic, papillary pattern and solid sheets 
[36]. The tumor cells are large with clear cytoplasm and nuclear hobnailing. [35]. 
IHC – CK7,  CA125 positive and negative for CK20. Bilateral in less than 10% 
of cases. They are aggressive tumors showing less response to chemotherapy 
than other ovarian carcinomas. They have a very high association with pelvic 
endometriosis. 
 
BRENNER TUMOR AND TRANSITIONAL CELL CARCINOMA 
 Constitute 1-2% of all ovarian neoplasms [36]. Some are accompanied by 
signs of hyperestrinism. Microscopically consist of nests of urothelium-like 
cells surrounded by abundant fibroblastic stroma. The nuclei may exhibit 
longitudinal grooves. Transitional cell carcinomas are those without the 
accompanying benign component. They all originate from surface ovarian 
epithelium through the process of metaplasia [37] 
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SQUAMOUS CELL TUMORS: 
 Primary squamous cell carcinoma ovary is exceedingly rare.They 
usually occur in ovaries as part of mature teratoma with malignant 
transformation of the squamous elements,or as metastasis from non-ovarian 
sources[119].Squamous elements may sometimes occur rarely as part of a 
metaplastic process in an endometrioid carcinoma ovary.Squamous cell 
carcinoma ovary is an aggressive ovarian tumor.CA-125 is either normal or is 
only mildly elevated in case of primary squamous cell carcinoma 
ovary.Presents radiologically as a heterogeneously echoic solid and cystic 
mass.Microscopically identified  with obvious invasion into the stroma.Keratin 
formation and intercellular bridges seen in well-differentiated forms.Treatment 
is surgery with adjuvant chemotherapy,but the prognosis is poor.[120]. 
 
MIXED EPITHELIAL TUMORS: 
 As per WHO classification,mixed epithelial tumors are those in which 
the minor component is easily recognizable and should constitute atleast 10% 
of the tumor on microscopic  examination.Mixed epithelial tumors ovary 
constitute <4% of all epithelial ovarian neoplasms.Serous-endometrioid,serous-
transitional,endometrioid-clear cell carcinoma types are the most frequent 
combinations seen[116].The dominant cell type determines the biological 
behaviour of the tumor.These tumors pose a diagnostic dilemma.Hence study 
of multiple sections of a tumor is recommended to exclude a mixed epithelial 
tumor.Mixed serous-endometrioid and serous-clear cell carcinomas usually are 
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a representation of high grade serous carcinoma with areas that mimic 
endometrioid and clear cell carcinoma.Clear cell carcinoma and endometrioid 
carcinoma usually arise in the setting of endometriosis and hence may occur in 
combination.In case of endometrioid and undifferentiated carcinoma occurring 
together,we need to exclude the possibility of dedifferentiated endometrioid 
carcinoma rather than a mixed epithelial tumor.[118]. 
 
MALIGNANT MIXED MULLERIAN TUMORS 
 More common in the uterus than in the ovary. The carcinomatous 
component maybe of serous, endometrioid, squamous or clear cells. The most 
common sarcomatous component is chondrosarcoma. Prognosis is extremely 
poor. 
 
ADENOSQUAMOUS CARCINOMA AND OTHER EPITHELIAL 
TUMORS 
Primary adenosquamous carcinoma of ovary is an extremely rare 
malignancy occurring in <1% of all malignant ovarian tumors [38]. 
Microscopically cells are arranged in sheets, glandular and focal papillary 
pattern. The cells show high grade pleomorphic vasicular nuclei. Also seen are 
cells showing malignant squamous differentiation with keratin pearls 
[39.]Because of the rarity,the optimal management of primary adenosquamous 
carcinoma ovary is unclear.Expression and immunohistochemical staining 
intensity of EGFR and VEGF has been noted to be stronger and more prevalent 
in squamous cell carcinoma compared to adenosquamous carcinoma.[115]. 
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UNDIFFERENTIATED CARCINOMA:  
These are a diagnosis of exclusion when the characteristic or diagnostic 
histological differentiating feature is absent.Before diagnosing this we need to 
exclude metastatic carcinomas and  other non-epithelial neoplasms.It is 
sometimes hard to elicit the epithelial differentiation of these tumors even with 
immunohistochemistry. 
 
PROGNOSTIC FACTORS 
1. Age – Younger patients show better outcome 
2. BRCA1 mutations and family history 
3. Tumour stage and grade 
4. Ascites – Unfavourable prognostic sign. 
5. Psammoma bodies  indicate better prognosis 
6. DNA ploidy – aneuploid tumors show higher grade. 
7. CA-125 levels. 
8. P53 – overexpression associated with poor prognosis 
9. Tumor angiogenesis 
10. Histological type. 
11. Intratumoral T cells 
12. Other markers including  EGFR, VEGF etc are all associated with 
aggressive behaviour 
. 
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TREATMENT 
Depends on tumour stage and grade. Surgery is the initial treatment of 
choice followed by chemotherapy with taxane or a platinum compound. Even 
in late stages, debulking surgery reduces the tumour burden. Primary 
cytoreductive surgery (at presentation) and secondary cytoreductive surgery 
(on recurrence) prolong the survival and progression free interval. 
 
Patients with advanced stage (FIGO III and IV) disease benefit from 
chemotherapy utilising platinum based compounds with or without a taxane. 
Platinum-based compounds have been shown to prevent extra abdominal 
metastasis. Paclitaxel has been found to be useful in many patients with 
platinum resistance. 
 
 Newer Modalities: Gefitinib – an EGFR (Epidermal Growth Factor 
Receptor) inhibitor has shown promise in the treatment of ovarian carcinoma 
since EGFR amplification is noted in about 20% to 80% of ovarian carcinomas. 
Bevacizumab – a VEGF (Vascular Endothelial Growth Factor) inhibitor is 
another drug showing promise in the ovarian carcinoma management [102] 
 
IMMUNOHISTOCHEMISTRY 
 IHC refers to the process of detecting antigens in cells, by using specific 
antibodies [40, 41]. The procedure was first initialized by Dr. Albert Coons in 
1941. A number of ways are present to visualize the antigen-antibody 
interaction [42] 
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 Some of the methods, are where the antibody is conjugated to an 
enzyme, like peroxidase which catalyzes a color producing reaction [43, 44] 
 
 Sometimes the antibody is tagged to a fluorophane like fluoroscein or 
rhodamine [45, 46, 47] 
 
STEPS IN IMMUNOHISTO CHEMISTRY 
1. Tissue processing and antigen or epitope retrieval. 
a. 10% neutral buffered formalin is the preferred fixative. 
b. These fixatives cause certain reversible changes in tertiary 
and quarternary structure of proteins [48, 49] 
c. Formalin fixed paraffin embedded tissue sections are cut 3 to 
4 microns thick and mounted on glass slides. 
d. Trypsin or protease enzyme digestion or  
e. Heating in buffered solutions example- citrate or EDTA 
buffer in either a microwave oven or pressure cooker” 
retrieves “or “unmasks “the antigens that have been altered by 
formalin fixation [50, 51, 52]. 
2. Antigen – antibody interaction 
Either the direct or indirect method can be used. 
3. Visualizing with detection systems 
Antibody molecules can be labelled with either fluorescent 
compounds or active enzymes. Horse radish peroxidase enzyme is 
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commonly used. The chromogens added thereafter are oxidized by 
horseradish peroxidase enzyme – giving a resultant brown/red 
colored IHC staining [53, 54, 55] 
 
EGFR 
 The epidermal Growth Factor Receptor structure- wise has an 
extracellular ligand binding domain, a transmembrane spanning region and an 
intracellular kinase containing domain [56, 57]. Activation of EGFR causes 
transmission of signals via intracellular MAPKS – Mitogen Activated Protein 
Kinases and protein kinase B causing a multitude of cellular responses like 
proliferation, cell motility and survival [58, 59, 60]. The EGFR gene is located on 
chromosome 7p12 [61, 62]. It is overexpressed in 9-62% of human ovarian 
cancers [63, 64]. Increased expression is linked with higher tumor grade, high 
proliferation index and poor patient outcome [65]. 
 
 The normal epithelial lining of ovary has got weak EGFR expression. 
Epithelial ovarian carcinomas show overexpression of EGFR in 4-100% of 
cases [103]. 
 
 Therapeutic implications of EGFR: Small molecule Tyrosine Kinase 
Inhibitors (TKIs) and monoclonal antibodies have been used currently in 
blocking EGFR activity. Erlotinib is the most common TKI. It is orally active, 
potent and also selectively inhibits EGFR Tyrosine Kinase. It binds reversibly 
to the ATP-binding site of EGFR and also inhibits autophosphorylation by 
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EGFR tyrosine kinase. This causes blockade of all subsequent EGFR signal 
transduction pathways producing cell cycle arrest. Next to EGFR TKIs, anti 
EGFR monoclonal antibodies like Cetuximab are the ones to be studied most 
extensively. [104] 
 
VEGF 
 A specific mitogen for vascular endothelial cells – the VEGF is a 
heparin binding dimeric polypeptide [66, 67]. For VEGF epithelial expression, 
about 5% of benign cystadenomas, 30% of borderline tumors and 80% of 
epithelial carcinomas showed positive staining [68, 69]. The expression of VEGF 
is increased in response to hypoxia, oncogenes and numerous cytokines. VEGF 
causes endothelial cell proliferation, cell migration and apoptosis inhibition. It 
also regulates angiogenesis [70]. 
 
 Though there are several angiogenic factors, VEGF (Vascular 
Endometrial Growth Factor) happens to be the single most robust molecule in 
the process of angiogenesis. There is a direct correlation of VEGF with 
intratumoral microvessel density. It heralds a poor prognosis in cancer patients. 
VEGF inhibition has been shown to reduce the tumour vessel density and 
tumour growth. 
 
 VEGF-A gene is located on chromosome – 6p12. Hyoxia Responsive 
Elements (HREs) are present in this gene. Hence Hypoxic conditions including 
Tumour hypoxia upregulates VEGF expression. VEGF induced angiogenesis is 
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responsible for malignant ascites production and eventual disease progression 
[105]. Even for patients with early stage disease, elevated VEGF levels were 
associated with significant risk of recurrence. 
 
VEGF targeting therapies 
Two primary strategies to inhibit the VEGF pathway are  
1. Inhibiting binding of VEGF ligand with antibodies 
2. Inhibiting binding of VEGF with tyrosine kinase inhibitors 
 
Bevacizumab 
 It is a 149 KDa recombinant humanized monoclonal anti-VEGF 
antibody. Two pivotal phase II trials have evaluated the efficacy of 
bevacizumab for the treatment of recurrent epithelial ovarian, peritoneal or 
tubal carcinoma. These trials showed a tremendous response rate of 20 – 60% , 
in achieving stable phase [106]. 
 
 Other VEGF receptor Tyrosine Kinase inhibitors that have been 
evaluated are Ramncirumab, Cediranib, Semoxanib, Sunitinib, Sorafenib, 
Vatalanib, Vandetanib, Intedanib, pazopanib etc… 
 
 Hence we find that VEGF is an attractive target for therapeutics and 
drug research in ovarian carcinoma 
 
Materials and Methods 
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MATERIALS AND METHODS 
 
 This study is a retrospective one conducted at Institute of Social 
Obstetrics and Govt Kasturba Gandhi Hospital for Women and Children, 
Madras Medical College, Chennai for a 3 year study period from 2013 to 2015. 
Out of the total 9313 cases of histopathological specimens received, 171 were 
ovarian neoplasms,out of which 92 were surface epithelial ovarian 
neoplasms.Out of these 92 suface epithelial ovarian neoplasms,62 were benign, 
4 were borderline and 26 were malignant. 
 
DATA COLLECTION 
 Case details especially age, complaints, procedure done,  grade and 
stage of tumors were obtained from pathology registers. Hematoxylin and 
Eosin sections of the paraffin tissue blocks were reviewed. Out of the 92 
surface epithelial ovarian neoplasms, 26 ovarian malignancies and 4 borderline 
tumors selected and their corresponding paraffin tissue blocks obtained for 
immunohistochemical analysis of EGFR and VEGF. 
 
TABLE  2:     PROCEDURE OF IMMUNOHISTOCHEMISTRY 
Antigen Vendor species (clone) Positive Control 
EGFR PathnSitu Rabbit monoclonal Squamous cell Carcinoma 
VEGF PathnSitu Mouse Monoclonal Kidney 
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1. 4 micron thick sections were cut from formalin fixed paraffin embedded 
tissue blocks and transferred onto gelatin –chrome-alum coated glass 
slides 
2. The glass slides were kept in an incubator at 58 degree Celsius overnight. 
3. Deparaffinisation in xylene for 15 minutes x 2 changes 
4. Dehydration with absolute alcohol for 5 minutes x 2 changes 
5. Washing of sections  done in tap water for 10 minutes 
6. Then in distilled water for 5 minutes 
7. Retrieval of antigen done with microwave oven with sections immersed 
in Tris EDTA buffer for 20 minutes 
a. 800 watts – 5 minutes 
b. 600 watts – 10 minutes 
c. 400 watts – 5 minutes 
8. Cool the slides to room temperature and then washed with distilled water 
for 10 minutes. 
9. Then washed in phosphate buffer for 5 minutes x 2 changes 
10.  Application of peroxidase block over the sections for 10 minutes 
11. Slides washed with phosphate buffer for 5 minutes. 
12. Appropriate primary antibody was applied over the sections and 
incubated for half an hour. 
13. After washing with wash buffer, polyexcel target binder reagent applied 
for 15 minutes. 
14. Slides were washed with 2 changes of buffer for 2 minutes. 
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15. Sections were covered with HRP micropolymer for 15 minutes 
16. Washed with phosphate buffer for 2 minutes 
17. 1 drop of DAB chromogen (prepared by diluting  1 drop of DAB 
chromogen to 1 mL of DAB buffer) was applied for 2-5 minutes 
18. Counterstaining was done with hematoxylin, washed in running tap 
water, air dried, cleared with xylene and mounted. 
 
INTERPRETATION AND SCORING 
 The IHC slides were analysed for the presence of the reaction, cellular 
localization of the staining – EGFR shows membrane and/or cytoplasmic 
staining. VEGF also shows cytoplasm and /or membrane staining. Percentage 
of tumor cells taking up the stain and the intensity with which they stain were 
also analysed. 
 
STATISTICAL ANALYSIS 
 Performed with package for social science software version 11.5. The 
expression of EGFR, VEGF were correlated and studied using student t-test 
and chi square test. 
 
Observation and Results 
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OBSERVATION AND RESULTS 
 In the 36-month study performed from June 2012 to June 2015, total of 
9313 specimen were received at  the Department of Pathology, Institute of 
social obstetrics and Govt. Kasturba Gandhi Hospital for women and children 
for histopathological examination. Out of the total  9313 cases, Ovarian 
specimen were 2435, of which, 171 were neoplastic, 1418 were normal and 
846 were non-neoplastic. 
 
 Thus ovarian specimen received constituted (26.15%) of the total 
histopathological specimen (Table 3, Chart 1) 
 
TABLE 3: FREQUENCY OF OVARIAN SPECIMEN AMONG TOTAL 
HISTOPATHOLOGICAL SPECIMEN 
 Count Percentage 
Ovarian Specimen 2435 26.15% 
Others 6878 73.85% 
 
CHART 1: FREQUENCY OF OVARIAN NEOPLASMS AMONG 
TOTAL HISTOPATHOLOGICAL SPECIMEN: 
 
26.15%
73.85%
Ovarian Specimen Others
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 Amidst ovarian lesions, 846 were non-neoplastic and 171 were neoplastic 
(Table 4, Chart 2). 
 
TABLE 4: FREQUENCY OF NONNEOPLASTIC  
AND NEOPLASTIC LESIONS OVARY 
 Count Percentage 
Neoplastic 171 7.02% 
Non neoplastic 846 92.98% 
 
CHART 2: FREQUENCY OF NON-NEOPLASTIC AND  
NEOPLASTIC LESIONS OVARY 
 
 
 
 Hence amidst total ovarian specimen of 2435, normal ovaries were 1418 
constituting 58.23%, non-neoplastic ovaries were 846 constituting 34.74% 
and neoplastic ovaries were 171 constituting 7.02%(Table 5,chart 3). 
7.02%
92.98%
Neoplastic Non neoplastic
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TABLE 5:FREQUENCY OF NORMAL, NEOPLASTIC AND  
NON-NEOPLASTIC OVARIES 
 
 Count Percentage 
Normal 1418 58.23% 
Neoplastic 171 7.02% 
Non neoplastic 846 34.74% 
 
CHART 3: FREQUENCY OF NORMAL, NEOPLASTIC AND  
NON-NEOPLASTIC OVARIES 
 
 
 Amidst 171 ovarian neoplasms, 92 were surface epithelial ovarian 
neoplasms that constituted 53.801% of total ovarian neoplasms, and hence 
topped the list of total ovarian neoplasms and were statistically significant 
(Table 6, Chart 4). 
  
58.23%
7.02%
34.74%
Normal Neoplastic Non-neoplastic
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TABLE 6: FREQUENCY OF EPITHELIAL OVARIAN NEOPLASMS 
 Count Percentage 
Epithelial-Ovarian 
Neoplasms 92 53.8% 
Others 79 46.2% 
 
CHART 4: FREQUENCY OF EPITHELIAL OVARIAN NEOPLASMS 
 
 
 Amidst 92 surface epithelial ovarian neoplasms, 62 were benign, 4 were 
borderline tumours and 26 were malignant (Table 7, Chart 5). 
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TABLE 7: FREQUENCY OF BENIGN ,BORDERLINE  AND 
MALIGNANT EPITHELIAL OVARIAN NEOPLASMS. 
 
 Count Percentage 
Benign 62 68% 
Borderline 4 4% 
Malignant 26 28% 
 
CHART 5: FREQUENCY OF BENIGN,BORDERLINE AND 
MALIGNANT EPITHELIAL OVARIAN NEOPLASMS. 
  
 
 Amidst the 62 benign ovarian surface epithelial tumors, the frequency of 
distribution of different histopathological types were-(Table 8, Chart 6) 
68%
4%
28%
benign
Borderline tumors
Malignant
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TABLE 8: HISTOMORPHOLOGICAL DISTRIBUTION OF BENIGN 
SURFACE EPITHELIAL OVARIAN NEOPLASMS: 
 
 Count Percentage 
Papillary serous cystadenoma 17 27.41% 
Benign serous cystadenoma 21 33.87% 
Benign mucinous cystadenoma 19 30.64% 
Benign Brenner 5 8.06% 
 
CHART 6: HISTOMORPHOLOGICAL DISTRIBUTION OF BENIGN 
SURFACE EPITHELIAL OVARIAN NEOPLASMS: 
 
 Amidst the 4 borderline tumours, 2 were atypical proliferating serous 
tumours (50%), 2 were atypical proliferating mucinous tumours (50%) 
(Table 9) 
27.41%
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TABLE 9: HISTOMORPHOLOGICAL  
DISTRIBUTION OF BORDERLINE TUMORS. 
 
 Count Percentage 
Atypical proliferating serous 
tumour 2 50% 
Atypical proliferating 
mucinous tumours 2 50% 
 
 Hence Benign serous tumours top the list constituting about 61.3% of 
total benign epithelial ovarian neoplasms, closely followed by benign mucinous 
cystadenomas that constituted about 30.64% of total benign epithelial ovarian 
neoplasms. 
 
 Amidst the 26 surface epithelial ovarian malignancies, the different 
histopathological types were as in (Table 10, Chart 7). 
 
TABLE 10:    HISTOMORPHOLOGICAL DISTRIBUTION OF 
SURFACE EPITHELIAL OVARIAN MALIGNANCIES 
 
 Count Percentage 
Papillary serous 
cystadenocarcinoma 9 34.61% 
Mucinous adenocarcinoma 4 15.38% 
Endometroid adenocarcinoma 8 30.76% 
Clear cell carcinoma 4 15.38% 
Adenosquamous carcinoma 1 3.81% 
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CHART 7:    HISTOMORPHOLOGICAL DISTRIBUTION OF 
SURFACE EPITHELIAL OVARIAN MALIGNANCIES 
 
 
 
 Benign epithelial ovarian neoplasms had a peak incidence at age group 
of 31 – 40 years that constitutes about 40.24% followed by the age group of 41 
– 50 years that formed about 24.38%. Mean age is about 33.33 years( Table 
11,Chart 8). 
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TABLE 11: AGE WISE DISTRIBUTION OF BENIGN EPITHELIAL 
OVARIAN NEOPLASMS 
Age group Number of cases Percentage 
21-30 years 5 10.97% 
31-40 years 29 40.24% 
41-50 years 16 24.38% 
51-60 years 9 15.86% 
>60 years 3 8.53% 
Total cases 62 100% 
 
CHART 8: AGE WISE DISTRIBUTION OF BENIGN EPITHELIAL 
OVARIAN NEOPLASMS 
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TABLE 12: AGE WISE DISTRIBUTION OF BORDERLINE 
EPITHELIAL OVARIAN NEOPLASMS 
Age group Number of cases Percentage 
31-40 years 1 25% 
41-50 years 2 50% 
51-60 years - - 
>60 years 1 25% 
Total cases 4 100% 
 
 Maximum  incidence of borderline epithelial ovarian neoplasms was 
found in the age group of 41-50 years. Mean age affected was found to be 
47.21 years (Table 12,Chart 9). 
 
CHART 9: AGE WISE DISTRIBUTION OF BORDERLINE 
EPITHELIAL OVARIAN NEOPLASMS. 
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TABLE 13:  AGE WISE DISTRIBUTION OF MALIGNANT 
EPITHELIAL OVARIAN NEOPLASMS 
Age group Number of cases Percentage 
41-50 years 8 30.76% 
51-60 years 10 38.46% 
61-70 years 7 26.92% 
>70 years 1 3.8% 
Total cases 26 100% 
 
 Maximum  incidence of malignant epithelial ovarian tumours was found 
in the age group of 51 to 60 years followed by 41 to 50 years. Mean age 
affected was found to be 54.5 years. (Chart 10). 
 
CHART 10:  AGE WISE DISTRIBUTION OF MALIGNANT 
EPITHELIAL OVARIAN NEOPLASMS 
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TABLE 14: GRADE WISE DISTRIBUTION OF MALIGNANT 
EPITHELIAL OVARIAN NEOPLASMS 
 
Grade Number of cases Percentage 
I 5 19.23% 
II 9 34.61% 
III 12 46.16% 
Total cases 26 100% 
 
We can see that maximum  tumours were in grade III (Chart 11). 
 
CHART 11: GRADE WISE DISTRIBUTION OF MALIGNANT 
EPITHELIAL OVARIAN NEOPLASMS 
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TABLE 15:    DISTRIBUTION OF MALIGNANT EPITHELIAL OVARIAN 
NEOPLASMS ACCORDING TO THE FIGO (INTERNATIONAL 
FEDERATION OF GYNAECOLOGY AND OBSTETRICS) STAGE. 
 
Stage Number of cases Percentage 
I 4 15.38% 
IIA 8 30.76% 
IIB 2 7.69% 
IIIB 5 19.23% 
IIIC 7 26.92% 
Total cases 26 100% 
 
CHART 12:    DISTRIBUTION OF MALIGNANT EPITHELIAL OVARIAN 
NEOPLASMS ACCORDING TO THE FIGO (INTERNATIONAL 
FEDERATION OF GYNAECOLOGY AND OBSTETRICS) STAGE. 
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CHART 13:    STAGE DISTRIBUTION AMONG MALIGNANT 
EPITHELIAL OVARIAN NEOPLASMS 
 
 
Hence, maximum presentation was in stage III (Chart 13). 
 
Results of ImmunohistoChemical Analysis 
 All the 26 malignant epithelial ovarian neoplasms and 4 borderline 
epithelial tumors were subjected to a panel of 2 immunohistochemical markers- 
EGFR(Epidermal Growth Factor Receptor)  and VEGF(Vascular Endothelial 
Growth Factor) 
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TABLE 16:    PERCENTAGE OF POSITIVE EXPRESSION OF EGFR, 
VEGF AMONG BORDERLINE OVARIAN NEOPLASMS 
 
IHC marker Positive Cases Negative Cases 
EGFR 2 (50%) 2 (50%) 
VEGF 3 (75%) 1 (25%) 
 
 Out of the four borderline ovarian neoplasms, 50% showed positivity for 
EGFR and another 50% showed negativity for EGFR. 
 
  Out of four borderline epithelial ovarian neoplasms, 75% showed 
positivity for VEGF. 
 
 
TABLE 17:  DISTRIBUTION OF POSITIVITY OF EGFR AND VEGF 
AMONG TYPES OF BORDERLINE EPITHELIAL OVARIAN 
NEOPLASMS. 
 
IHC marker APST Positive (%) 
APMT Positive 
(%) Total 
EGFR 2 (100%) Nil positive 4 
VEGF 2 (100%) 1 (50%) 4 
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TABLE 18:   DISTRIBUTION OF POSITIVITY AMONG MALIGNANT 
EPITHELIAL OVARIAN NEOPLASMS 
IHC marker Positive cases (%) 
Negative cases 
(%) Total 
EGFR 21 (80.76%) 5 (19.23%) 26 (100%) 
VEGF 22 (84.62%) 4 (15.38%) 26 (100%) 
 
 Out of the total 26 malignant epithelial ovarian neoplasms, 21 (80.76%) 
of them showed positivity for EGFR and 19.23% of them were negative for 
EGFR (Table 18, Chart 14). 
 
CHART 14:  DISTRIBUTION OF POSITIVITY AMONG MALIGNANT 
EPITHELIAL OVARIAN NEOPLASMS 
 Out of the total 26 malignant epithelial ovarian neoplasms, 22 (84.62%) 
of them showed positivity for VEGF while only 4 (15.38%) of them were 
negative for VEGF. 
81%
19%
Postive
Negative
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TABLE 19:    DISTRIBUTION OF POSITIVITY OF EGFR AND VEGF 
AMONG TYPES OF MALIGNANT EPITHELIAL OVARIAN 
NEOPLASMS. 
Histopathological 
type of malignant 
ovarian 
neoplasm 
EGFR 
Positive 
EGFR 
Negative 
VEGF 
Positive 
VEGF 
Negative Total 
Papillary serous 
cystadeno 
carcinoma 
8 
(88.89%) 
1 
(11.11%) 
8 
(88.89%) 
1 
(11.11%) 
9 
(100%) 
Endometroid 
adenocarcinoma 7 (87.5%) 
1 
(12.5%) 7 (87.5%) 
1 
(12.5%) 
8 
(100%) 
Mucinous 
adenocarcinoma 2 (50%) 2 (50%) 3 (75%) 1 (25%) 
4 
(100%) 
Clear cell 
carcinoma 4 (100%) Nil 4 (100%) Nil 
4 
(100%) 
Adenosquamous 
carcinoma Nil positive Nil positive 
1 
(100%) 
 
Thus, we can infer that – 
 88.89% of papillary serous cystadenocarcinoma ovary showed positivity for 
both EGFR and VEGF.  
 87.5% of endometroid adenocarcinoma ovary showed positivity for both 
EGFR and VEGF.  
 Only 50% of mucinous adenocarcinoma showed positivity for EGFR while 
75% of them showed positivity for VEGF 
 All the clear cell carcinomas – (100% of them) showed positivity for both 
EGFR and VEGF 
 The adenosquamous carcinoma that was evaluated did not show positivity 
for either EGFR or VEGF. 
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TABLE 20:  TABLE FOR COMPARISON OF INTENSITY OF EXPRESSION 
OF EGFR AND VEGF AMONG BORDERLINE TUMORS AND 
MALIGNANT EPITHELIAL OVARIAN TUMORS. 
 
 EGFR Total NEGATIVE 2+ 3+ 
MALIGNANT 
TUMOURS 
Count 5 5 16 26 
% within 
EGFR 71.4% 71.4% 100.0% 86.7% 
BORDERLINE 
TUMOURS 
Count 2 2 0 4 
% within 
EGFR 28.6% 28.6% 0.0% 13.3% 
Total 
Count 7 7 16 30 
% within 
EGFR 100.0% 100.0% 100.0% 100.0% 
 
P=0.042 
CHART 15: TABLE FOR COMPARISON OF INTENSITY OF EXPRESSION 
OF EGFR AND VEGF AMONG BORDERLINE TUMORS AND 
MALIGNANT EPITHELIAL OVARIAN TUMORS. 
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CHART 16:  PERCENTAGE OF EGFR  POSITIVITY AMONG 
BORDERLINE AND MALIGNANT EPITHELIAL OVARIAN NEOPLASMS. 
 
 
 From this, we infer that 86.7% of malignant epithelial ovarian tumours 
showed varying degrees of positivity for EGFR while only 13.3% of borderline 
epithelial tumours showed positivity. The P value was calculated as 0.042 and 
hence this correlation was found statistically significant (Table 20,Chart 16.). 
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TABLE 21:   PERCENTAGE OF EXPRESSION OF EGFR IN  
MALIGNANT EPITHELIAL OVARIAN NEOPLASMS. 
HPE 
EGFR 
Total 
NEGATIVE 2+ 3+ 
Papillary Serous 
Cystadenocarcinoma 
Count 1 3 5 9 
% 11.11% 33.33% 55.56% 100.00% 
Endometrioid 
adenocarcinoma of 
ovary 
Count 1 2 5 8 
% 12.50% 25.00% 62.50% 100.00% 
Mucinous 
adenocarcinoma ovary 
Count 2 0 2 4 
% 50.00% 0.00% 50.00% 100.00% 
Clear cell carcinoma 
ovary 
Count 0 0 4 4 
% 0.00% 0.00% 100.00% 100.00% 
Adenosquamous 
carcinoma ovary 
Count 1 0 0 1 
% 100.00% 0.00% 0.00% 0.00% 
Borderline tumors 
Count 2 2 0 4 
% 50.00% 50.00% 0.00% 13.30% 
Total 
Count 7 7 16 30 
% 23.33% 23.33% 53.33% 100.00% 
 
 From this table we infer that nearly 100% of clear cell carcinomas 
studied, 62.5% of endometroid carcinomas studied, 55.56% of papillary serous 
carcinomas studied and 50% of mucinous carcinomas studied showed EGFR 
positivity. (Table 21,Chart 17). 
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CHART 17:   PERCENTAGE OF EXPRESSION OF EGFR IN BORDERLINE 
TUMORS AND MALIGNANT EPITHELIAL OVARIAN NEOPLASMS. 
 
 
 
TABLE 22  : CORRELATION OF TUMOR GRADE  
WITH EGFR EXPRESSION 
 EGFR Total NEGATIVE 2+ 3+ 
Tumor 
grade 
1.00 
Count 4 2 0 6 
% within 
EGFR 57.1% 28.6% 0.0% 20.0% 
2.00 
Count 2 5 3 10 
% within 
EGFR 28.6% 71.4% 18.8% 33.3% 
3.00 
Count 1 0 13 14 
% within 
EGFR 14.3% 0.0% 81.2% 46.7% 
Total 
Count 7 7 16 30 
% within 
EGFR 100.0% 100.0% 100.0% 100.0% 
 
P<0.001 
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 In this study, 81.2% of grade III tumours showed 3+ EGFR positivity. 
Higher the grade, higher was the expression of EGFR and this correlation was 
statistically highly significant since the P value was less than 0.001(Table 
22,Chart 18). 
 
CHART 18:   CORRELATION OF TUMOR GRADE WITH EGFR 
EXPRESSION 
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TABLE 23:    CORRELATION OF TUMOR STAGE WITH EGFR 
EXPRESSION 
 
EGFR 
Total 
NEGATIVE 2+ 3+ 
Stage 
 
Count 2 2 0 4 
% within 
EGFR 28.6% 28.6% 0.0% 13.3% 
II A 
Count 3 3 4 10 
% within 
EGFR 42.9% 42.9% 25.0% 33.3% 
II B 
Count 1 1 0 2 
% within 
EGFR 14.3% 14.3% 0.0% 6.7% 
III 
B 
Count 0 1 5 6 
% within 
EGFR 0.0% 14.3% 31.2% 20.0% 
III 
C 
Count 1 0 7 8 
% within 
EGFR 14.3% 0.0% 43.8% 26.7% 
Total 
Count 7 7 16 30 
% within 
EGFR 100.0% 100.0% 100.0% 100.0% 
 
P= 0.039 
 
 In this study 75% of stage III tumors showed 3+ positivity. Higher the 
stage, higher was the expression of EGFR and this correlation was statistically 
significant since P value was 0.039(Table 23,Chart 19). 
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CHART 19   CORRELATION OF TUMOR STAGE  
WITH EGFR EXPRESSION 
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TABLE 24:  TABLE FOR COMPARISON OF INTENSITY OF VEGF 
EXPRESSION AMONG BORDERLINE AND MALIGNANT 
EPITHELIAL OVARIAN TUMORS 
 
 
VEGF 
Total 
NEGA 
TIVE 1+ 2+ 3+ 
MALIGNANT 
TUMOURS 
Count 4 0 4 18 26 
% 
within 
VEGF 
80.0% 0.0% 66.7% 100.0% 86.7% 
BORDERLINE 
TUMOURS 
Count 1 1 2 0 4 
% 
within 
VEGF 
20.0% 100.0% 33.3% 0.0% 13.3% 
Total 
Count 5 1 6 18 30 
% 
within 
VEGF 
100.0% 100.0% 100.0% 100.0% 100.0% 
 
P=0.009 
 
 From this we infer that 86.7% of malignant epithelial ovarian tumors 
showed varying degrees of positivity for VEGF while only 13.3% of borderline 
tumors showed VEGF positivity. The P value 0.009 shows that this correlation 
was statistically significant (Chart 20). 
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CHART 20:  TABLE FOR COMPARISON OF INTENSITY OF VEGF 
EXPRESSION AMONG BORDERLINE AND MALIGNANT 
EPITHELIAL OVARIAN TUMORS 
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TABLE 25:     CORRELATION OF VEGF WITH HISTOPATHOLOGICAL 
TYPES OF MALIGNANT EPITHELIAL OVARIAN NEOPLASMS 
 
VEGF 
Total 
NEGATIV
E 1+ 2+ 3+ 
HPE 
Papillary Serous 
Cystadeno 
carcinoma 
Count 1 0 1 7 9 
% within 
VEGF 11.11% 0.00% 11.11% 77.78% 100.00% 
Endometrioid 
adenocarcinoma 
of  ovary 
Count 1 0 2 5 8 
% within 
VEGF 12.50% 0.00% 25.00% 62.50% 100.00% 
Mucinous 
adenocarcinoma 
ovary 
Count 1 0 1 2 4 
% within 
VEGF 25.00% 0.00% 25.00% 50.00% 100.00% 
Clear cell 
carcinoma ovary 
Count 0 0 0 4 4 
% within 
VEGF 0.00% 0.00% 0.00% 100.00% 100.00% 
Adenosquamous 
carcinoma ovary 
Count 1 0 0 0 1 
% within 
VEGF 100.00% 0.00% 0.00% 0.00% 100.00% 
Borderline 
tumors 
Count 1 1 2 0 4 
% within 
VEGF 25.00% 25.00% 50.00% 0.00% 100.00% 
Total 
Count 5 1 6 18 30 
% within 
VEGF 16.67% 3.33% 20.00% 60.00% 100.00% 
 
 This table shows that nearly 100% of clear cell carcinomas studied, 
77.78% of papillary serous carcinomas studied, 62.5% of endometroid 
carcinomas studied, and 50% of mucinous carcinomas studied showed VEGF 
positivity (Chart 19). 
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CHART 21:   CORRELATION OF VEGF WITH 
HISTOPATHOLOGICAL TYPES OF MALIGNANT EPITHELIAL 
OVARIAN NEOPLASMS 
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TABLE 26:    CORRELATION OF TUMOR GRADE WITH VEGF 
EXPRESSION 
Crosstab 
 
VEGF 
Total NEGA
TIVE 1+ 2+ 3+ 
Gra
de 
1.0
0 
Count 2 1 3 0 6 
% within 
VEGF 40.0% 
100.0
% 50.0% 0.0% 20.0% 
2.0
0 
Count 2 0 3 5 10 
% within 
VEGF 40.0% 0.0% 50.0% 27.8% 33.3% 
3.0
0 
Count 1 0 0 13 14 
% within 
VEGF 20.0% 0.0% 0.0% 72.2% 46.7% 
Total 
Count 5 1 6 18 30 
% within 
VEGF 100.0% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
 
P=0.006. 
 
 In this study, 72.2% of grade 3 tumors showed 3+ VEGF positivity. 
Higher the grade, higher was the expression of VEGF and this correlation was 
found to be statistically significant as P value was 0.006(Chart 20). 
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CHART 22   CORRELATION OF TUMOR GRADE WITH VEGF 
EXPRESSION 
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TABLE 27:    CORRELATION OF TUMOR STAGE WITH VEGF 
EXPRESSION 
 
 
VEGF 
Total NEGA
TIVE 1+ 2+ 3+ 
Sta
ge 
 
Count 1 1 2 0 4 
% within 
VEGF 20.0% 
100.0
% 33.3% 0.0% 13.3% 
II 
A 
Count 2 0 3 5 10 
% within 
VEGF 40.0% 0.0% 50.0% 27.8% 33.3% 
II 
B 
Count 1 0 1 0 2 
% within 
VEGF 20.0% 0.0% 16.7% 0.0% 6.7% 
III 
B 
Count 0 0 0 6 6 
% within 
VEGF 0.0% 0.0% 0.0% 33.3% 20.0% 
III 
C 
Count 1 0 0 7 8 
% within 
VEGF 20.0% 0.0% 0.0% 38.9% 26.7% 
Total 
Count 5 1 6 18 30 
% within 
VEGF 100.0% 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
P=0.043 
 In this study 72.2% of stage III tumors showed 3+ VEGF positivity. 
Higher the stage, higher was the expression of VEGF and this correlation was 
found to be statistically significant since P value was 0.043. (Chart 23) 
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CHART  23:     CORRELATION OF TUMOR STAGE  
WITH VEGF EXPRESSION. 
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Figure 1:HPE NO:1842/15,Papillary serous cystadeno  carcinoma ovary 
 
 
 
 
 
Figure 2: HPE NO:3160/15,Endometrioid adenocarcinoma ovary 
 
 
 
  
Figure 3:HPE NO:877/15 Mucinous adenocarcinoma ovary 
 
 
 
 
 
Figure 4:HPE NO:254/15 Clear cell adenocarcinoma ovary 
 
  
 
 
 
Figure 5:HPE NO:404/14 Adenosquamous carcinoma ovary. 
 
 
 
 
 
Figure 6:HPE NO:305/13-Atypical Proliferating Serous Tumour 
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305/13 
 
 
 
IHC Profile of papillary serous cystadenocarcinoma 
 
 
 
 
 
 
 
   
Figure 7: H&E-High power view 
  
Figure 8:EGFR Score 3+ Figure 9:VEGF Score 3+ 
 
 
  
 
 
Papillary serous cystadenocarcinoma 
  
Figure 10:EGFR score 2+ Figure 11:VEGF score 2+ 
 
 
 
 
 
Endometrioid adeno carcinoma 
  
Figure 12:EGFR score 2+ Figure 13:VEGF score 2+ 
 
  
 
 
 
IHC Profile of endometrioid adenocarcinoma ovary 
 
 
Figure 14:H&E High power view 
  
Figure 15:EGFR Score 3+ Figure 16:VEGF Score 3+ 
 
 
  
 
 
 
IHC Profile of mucinous adenocarcinoma ovary 
 
 
Figure 17:H&E High power view 
  
Figure 18:EGFR Score 3+ Figure 19:VEGF Score 3+ 
 
 
 
  
 
 
 
IHC Profile of clear cell adenocarcinoma 
 
 
Figure 20:H&E High power view 
  
Figure 21:EGFR Score 3+ Figure 22:VEGF Score 3+ 
 
  
 
 
 
IHC Profile of adenosquamous carcinoma 
        
  
Figure 23:H&E High power view 
  
Figure 24:EGFR Negative Figure 25:VEGF Negative 
 
  
 
 
 
IHC Profile of borderline tumors ovary 
        
  
Figure 26:H&E Low power view 
  
Figure 27:EGFR Positive, 
low power view 
Figure 28:VEGF Positive, 
low power view 
  
Figure 29:EGFR Score 3+  
High power view 
Figure 30:VEGF Score 3+  
High power view 
 
Discussion 
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DISCUSSION 
 
 Carcinoma ovary is the fourth leading cause of death among women. 
Amidst neoplasms of female genital tract, ovarian carcinoma carries maximum 
morbidity and mortality as there are no easy or effective screening techniques 
and most of the ovarian neoplasms present at advanced stage,since early stages 
are predominantly asymptomatic.    
 
 In the study by Vijaykumar et at [109], involving 150 cases of ovarian 
specimen sent for histopathology at Govt Medical College, Patiala Punjab, 40% 
(60 cases) were neoplastic and 60% (90 cases) were non neoplastic 
 
 In the study by Layla et al [110], on  pattern of ovarian neoplasms in 
Saudi Arabia, out of 618 ovarian specimen studied, 61.8% were ovarian 
neoplasms while 38.2% were non neoplastic 
 
 In a study of 145 cases by Kanithkar et al from  Maharashtra, 75% were 
non neoplastic and 25% were neoplastic.  
 
 In our current study involving 2435 ovarian specimen, 34.74% were 
non-neoplastic, while 7.02% were neoplastic. 
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TABLE 28 – PERCENTAGE OF NEOPLASTIC AND NON 
NEOPLASTIC OVARIAN LESIONS IN VARIOUS STUDIES 
 
Study Non neoplastic percentage Neoplastic percentage 
Vijaykumar et al (150 
cases) 60% 40% 
Layla et al (618 cases) 38.2% 61.8% 
Kanithkar et al (145 
cases) 75% 25% 
Current study 34.74% 7.02% 
 
  In the sudy by Prakashiny et al [112] involving 80 cases of ovarian 
neoplasms, benign ovarian tumors accounted for 72.5% while malignant 
tumors accounted for 27.5%. 
 
 In the study by GG Swamy et al involving 120 cases, 86 were benign 
and 24 were malignant, constituting 71.6% and 28.4% respectively. 
 
 In the study by Kanithkar et al involving 145 cases, 78.57% were benign 
while 21.43% were malignant [111] 
 
 In the study by Mankar DV et al of the total 257 cases of ovarian 
tumors, 63.04% were benign while 36.96% were malignant [114] 
 
 In the study by Layla et al [110], of the 382 ovarian neoplasms, benign 
ones constituted 72.8% while malignant ones were about 27.2%. 
 
 While in our current study of 171 ovarian neoplasms 71.1% were 
benign, while 28.9% were malignant. 
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TABLE 29 – PERCENTAGE OF BENIGN AND OVARIAN 
NEOPLASMS IN VARIOUS STUDIES 
 
Study Benign ovarian neoplasms’ percentage 
Malignant ovarian 
neoplasms’ percentage 
Prakashiny et al 72.5% 27.5% 
GG Swamy et al 71.6% 28.4% 
Kanithkar S.N et al 78.57% 28.43% 
Mankar DV et al 63.04% 36.90% 
Layla et al 72.8% 27.2% 
Current study 71.1% 28.9% 
 
 In the study by Prakashiny et al [112], of 80 cases of ovarian neoplasms, 
surface epithelial ovarian tumors constituted 61.25% of the total. 
 
 The study by GG Swamy et al [113] of 120 cases of ovarian neoplasms 
showed that 61.6% of them were of surface epithelial type. 
 
 Kanithkar SN [111] et al studied 145 cases and showed that, surface 
epithelial ovarian tumors were commonest (67.14%) [111] 
 
 In the study by Mankar DV et al [114], 257 cases of ovarian tumors were 
studied of which 68.48% were surface epithelial ovarian neoplasms. 
 
 In our current study, of the 171 ovarian neoplasms, 53.801% were of 
surface epithelial type. 
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TABLE 30 – COMPARISON OF PERCENTAGE OF SURFACE EPITHELIAL 
OVARIAN NEOPLASMS AMONG TOTAL IN VARIOUS STUDIES: 
 
Study Surface epithelial ovarian neoplasms’ percentage 
Prakashiny et al 61.25% 
GG Swamy et al 61.6% 
Kanithkar S.N et al 67.14% 
Mankar DV et al 68.48% 
Layla et al 61% 
Current study 53.801% 
 
In the study by Prakashiny et al [112], simple serous cystadenoma 
(52.5%) accounted for majority of benign epithelial tumors among a total of 80 
ovarian lesions. 
 
 In the study by GG Swamy et al [113] of 120 cases, the most common 
benign epithelial tumor was noted to be serous cystadenoma (40.8%). 
 
 Kanithkar SN [111] et al in his study of 145 ovarian neoplasms, found that 
the majority of benign epithelial tumors were of benign serous cystadenoma 
category constituting about 39.8%. 
 
 In the study of 257 cases of ovarian tumors by Mankar DV et al [114], 
mucinous cystadenoma topped the list of benign epithelial tumors. 
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Layla et al [110] studied 382 cases of ovarian tumors and concluded that 
serous cystadenoma formed the major bulk of benign epithelial tumors 
constituting (34.48%) of total benign epithelial tumors. 
 
In our current study, serous cystadenoma was found to be the most 
frequent benign epithelial tumor constituting 61.28% of total benign epithelial 
tumors. 
 
TABLE 31 – THE MOST COMMON BENIGN EPITHELIAL  
TUMOR IN VARIOUS STUDIES 
 
Study Most common benign epithelial tumor 
Prakashiny et al Benign serous cystadenoma 
GG Swamy et al Benign serous cystadenoma 
Kanithkar S.N et al Benign serous cystadenoma 
Mankar DV et al Mucinous cystadenoma 
Layla et al Serous cystadenoma 
Current study Serous cystadenoma 
 
In the study by Prakashiny et al [112], serous papillary 
cystadenocarcinoma (35.6%) formed majority of surface epithelial 
malignancies out of a total of 80 cases. 
 
 The study by GG Swamy et al [113] of 120 cases, the most common 
malignant epithelial tumor was noted to be endometrioid adenocarcinoma 
(40.8%). 
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 Kanithkar SN [111] et al in his study of 145 ovarian neoplasms, found that 
the majority of malignant epithelial ovarian tumors were of serous 
cystadenocarcinoma  category constituting about 37.67% of all malignant 
epithelial ovarian tumors. 
 
 In the study of 257 cases of ovarian  tumors by Mankar DV et al [114], 
serous cystadenocarcinoma (31.13%) topped the list of malignant epithelial 
ovarian tumors. 
 
Layla et al [110] studied 382 cases of ovarian tumors and concluded that 
serous cystadenocarcinoma  formed the major bulk of malignant epithelial 
tumors constituting about 38.84% of total malignant epithelial tumors. 
 
In our current study, papillary serous cystadenocarcinoma  constituted 
the major bulk of malignant epithelial tumors. 
 
TABLE 32:MOST FREQUENT MALIGNANT EPITHELIAL TUMOR IN 
VARIOUS STUDIES. 
Study Most frequent malignant epithelial tumor 
Prakashiny et al Serous papillary cystadenocarcinoma 
GG Swamy et al Endometrioid adenocarcinoma 
Kanithkar S.N et al Serous cystadenocarcinoma 
Mankar DV et al Serous cystadenocarcinoma 
Layla et al Serous cystadenocarcinoma 
Current study Serous cystadenocarcinoma 
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 In this study, Immunohistochemical evaluation was attempted on the 30 
borderline and malignant epithelial ovarian neoplasms received at the institute 
of social obstetrics and Government Kasturba Gandhi Hospital for women and 
children. Madras Medical College, Chennai in the 3-year period between June 
2012 and June 2015. 
 
 Comparison of age distribution of benign epithelial ovarian tumors in 
the present study and other studies. 
 
Age group 
 In the study by Verma and Bhatia et al (1981), Inamdar et al (2015) 
maximum incidence of benign epithelial ovarian tumors was found at age 
group of 21 to 40 years which is similar to the current study [71](Table 26). 
 
TABLE 33: COMPARISON OF AGE AMONG BENIGN TUMORS 
STUDY AGE GROUP WITH MAXIMUM INCIDENCE 
Inamdar et al (2015)(87 cases) 21 – 40 years 
Verma et al (1981)(103 cases) 21 – 40 years 
Current study 21-40 years 
 
 In the study by Jagadeshwari et al (1971) [72] by Bhatia et all (1981) [73] 
and Inamdar et al (2015) maximum incidence of malignant epithelial ovarian  
neoplasms was found at age range of 41 to 60 years which is similar to the 
current study (Table 34). 
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TABLE 34:   COMPARISON OF AGE AMONG  
MALIGNANT EPITHELIAL OVARIAN TUMORS. 
 
STUDY AGE GROUP WITH MAXIMUM INCIDENCE. 
Jagadeshwari et al (1971)(56 cases) 41 – 60 years 
Bhatia et all (1981)(79 cases) 41 – 60 years 
Current Study(30 cases) 41 – 60 years 
 
Tumor grade 
 In the study by Bashir Ahmad et al, poorly differentiated (grade III) 
tumors topped the list among different, malignant epithelial ovarian neoplasms, 
constituting 48.4%,which are similar to the current study where the frequency 
of grade 3 tumors was found to be 46.7%. 
 
TABLE 35 :    PERCENTAGE OF GRADE III  
TUMORS IN VARIOUS STUDIES 
 
STUDY PERCENTAGE OF GRADE III TUMOURS 
Bashir Ahmed et al [74] (64 cases) 48.4% 
Current Study (30 cases) 46.7% 
 
Tumor  stage 
 In the study by Mohamed Farouk et al, percentage of epithelial ovarian 
carcinomas presenting at Stage III was given as 50.6% [75,76] which are similar 
to the current study where maximum cases presented  in the late stage III 
constituting about 46.15%. 
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TABLE 36:   PERCENTAGE OF MALIGNANT EPITHELIAL OVARIAN 
TUMORS PRESENTING AT STAGE III IN DIFFERENT STUDIES. 
Current Study Mohamed et al  (2012) 
Michelle et al  
(2009) 
46.15% 
(30 cases) 
50.6% 
(53 cases) 
61.01% 
(44 cases) 
 
Immunohistochemical Analysis 
 Structurally EGFR is made of an extracellular ligand binding domain, a 
single transmembrane spanning region, and an intracellular region containing 
the kinase activity [77,78] Activation of EGFR causes transduction of EGFR 
signals via MAPK (Mitogen Activated Protein Kinase) and AKT (protein 
Kinase B) pathways, triggering a number of cellular responses like 
proliferation, differentiation, cell motility and survival [79,80]. The chromosome 
7p12 contains the EGFR gene which is expressed in most of ovarian 
carcinomas and is associated with poor prognosis. [81,82]. 
 
 The epithelial lining of the ovary normally has weak EGFR 
expression.Epithelial ovarian neoplasms including borderline and epithelial 
ovarian carcinomas show EGFR overexpression ranging from( 4% to 60%) and 
(30% to 100% of cases) respectively.[83,84] while in our study, 50% of 
borderline epithelial ovarian neoplasms and 80.76% of malignant epithelial 
ovarian neoplasms showed EGFR expression. Similar to breast and bladder 
cancer, expression of EGFR in ovarian cancer appears to be a poor prognostic 
factor [85]. EGFR amplification was found to increase with grade of ovarian 
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tumour [86]. EGFR overexpression has been found to be associated with high 
tumour grade and stage, high cell proliferation index and poor survival rate for 
the patient [87]. The percentage of ovarian epithelial cancers overexpressing 
EGFR range from 63% to 100% (Alper et al 2001, Sewell et al 2002, 
Skirnisdottir et al 2001) [88]. Even in our current study 80.76% of malignant 
epithelial ovarian tumours showed EGFR positivity. In our current study, 
statistically significant correlation existed between EGFR expression and 
tumour grade and stage as the P value was 0.001 and 0.039 respectively 
 
TABLE 37: PERCENTAGE OF EPITHELIAL OVARIAN CANCERS 
OVEREXPRESSING EGFR IN VARIOUS STUDIES [88] 
STUDY PERCENTAGE 
Alper et al (2001) (64 cases) 72% 
Sewell et al (2002) (49 cases) 63% 
Skirnis dotit et al (2001) (22 cases) 65% 
Current study (2015) (30 cases) 80.76% 
 
VEGF 
 The dimeric glycoprotein Vascular Endothelial Growth Factor(VEGF)  
has got potent mitogenic effect on endothelial cells. It plays an important role 
in regulation of angiogenesis process during embryogenesis. It also plays a 
vital role in cancer – neoangiogenesis [89]. VEGF is a multifunctional cytokine 
that causes increase in microvascular permeability and density,  nourishing the 
highly metabolic tumor cells and also provides access to the host 
vasculature[89]. 
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 In the study by Jun Wang et al, only 30% of borderline epithelial 
ovarian tumours and 80% of malignant epithelial ovarian tumours were 
positive for VEGF expression [89]. 
 
 In the study by S.Yamamoto et al, 97% of ovarian carcinomas showed 
positive immunostaining for VEGF while 52% of borderline epithelial ovarian 
tumours showed positivity [90] 
 
 In the study by Hel, Zhao X et al, 80% of ovarian carcinomas, 21% of 
borderline epithelial ovarian tumours showed positive VEGF immunostaining 
[91].  
 
 In our present study, positive VEGF expression was found in 75% of 
borderline and 84.62% of malignant epithelial ovarian tumors. 
 
 
TABLE 38                             VEGF Positivity 
Study 
Percentage positivity in 
Borderline  
epithelial  tumors 
Malignant ovarian  
epithelial tumors 
Jun Wang et al(27 cases) 30 80 
Yamomoto et al(55 cases) 52 97 
Hel, Zhao X et al(37 cases) 21 80 
Current Study(30 cases) 75 84.62 
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 VEGF expression showed statistically significant correlation between 
FIGO stage and lymph node metastasis [91] 
 
 VEGF gene expression was positively correlated with Stage III & IV 
ovarian epithelial cancers [92] 
 
 Even in our present study, there was a positive correlation of VEGF with 
tumor grade or stage with P value of 0.006 and 0.043 respectively. 
 
  
Summary 
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SUMMARY 
 
 For the study period of 3 years from 2012 to 2015, total of 9313 
histopathological specimens were received at Department of pathology, 
Institute of social obstetrics and Government Kasturba Gandhi Hospital for 
women and children. 
 Amidst 9313 cases, 2435 were ovarian specimens. 
 Amidst 2435 ovarian specimen,1418 were normal,846 were non 
neoplastic,171 were neoplastic. 
 Amidst 171 ovarian neoplasms,  92 (53.81%) were surface epithelial 
ovarian neoplasms. 
 Out of 92 surface epithelial ovarian neoplasms, 62 were benign, 4 were 
borderline and 26 were epithelial ovarian malignancies. 
 Out of the 62 benign ovarian neoplasms, 61.3% were that of benign serous 
cystadenoma and papillary serous cystadenoma, 30.64% were that of 
benign mucinous cystadenoma and only 8.06% were of  benign Brenner 
type. 
 Out of 4 borderline tumors, 2 were that of atypical proliferating serous 
tumors and 2 were that of atypical proliferating mucinous tumors. 
 Amidst the 26 epithelial ovarian carcinomas, papillary serous 
cystadenocarcinomas topped the list constituting about 34.61% of total, 
followed closely by endometrioid adenocarcinomas that constituted 30.76% 
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of the total followed by clear cell carcinoma and adenosquamous 
carcinoma. 
 Maximum incidence of benign neoplasms was found to be in age group of 
31 to 40 years. Peak incidence of borderline ovarian tumors was found in 41 
to 50 years age group. 51 to 60 years  age group showed maximum 
incidence of malignant epithelial ovarian neoplasms. 
 Amidst total malignancies, grade III tumors contributed maximum 
percentage with 46.14% 
 Maximum tumors presented at an advanced stage - stage III-constituting 
46.15% of them. 
 Out of 4 borderline ovarian neoplasms, 50% showed positivity for EGFR 
while 75% of them showed positivity for VEGF. 
 Among malignancies, 80.76% of them showed EGFR positivity while 
84.02%  showed VEGF positivity.  
 Amidst malignancies, nearly 100% of clear cell carcinomas, 50% of 
mucinous carcinomas, and 87.5% of endometrioid adenocarcinomas while 
88.89% of papillary serous carcinomas showed positive immunostaining for 
EGFR. 
 Similarly nearly 100% of clear cell carcinomas, 88.89% of papillary serous 
carcinomas,87.5% of endometrioid adenocarcinomas, 75% of mucinous 
carcinoma showed positive immunostaining for VEGF. 
 The Adenosquamous carcinoma that was evaluated showed neither 
positivity for EGFR nor VEGF. 
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 While only 13.3% of borderline epithelial tumors showed EGFR positivity 
86.7% of carcinomas showed varying degrees of EGFR positivity. P value 
0.042 shows that this correlation was statistically significant. 
 81.2% of grade III tumors showed 3+ EGFR positivity.  EGFR expression 
increased with grade of the tumor and this correlation was found 
statistically significant since the P value was 0.001. 
 75% of stage III tumors showed 3+ EGFR positivity. EGFR expression was 
increased with stage of the tumor and this correlation was found statistically 
significant since the P value was 0.039. 
 85.7% of malignant epithelial neoplasms showed varying degrees of 
positivity for VEGF while only 14.3% of borderline tumors showed VEGF 
positivity.  P value 0.009 shows that the correlation was statistically 
significant. 
 72.2% of grade 3 tumors showed 3+ VEGF positivity. Higher the grade, 
higher was the expression and this correlation was found statistically 
significant with P value 0.006. 
 72.2% of stage III tumors showed 3+ VEGF positivity. Advanced stage 
tumors showed increased expression of VEGF and this correlation was 
statistically significant with P value calculated as 0.043. 
 
  
Conclusion 
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CONCLUSION 
 
 To conclude, we can say that like all other studies even in this study – 
the surface epithelial ovarian neoplasms were found to be statistically the most 
significant one contributing 53.81% of the total ovarian neoplasms. Even 
among surface epithelial tumours, benign neoplasms significantly outnumbered 
the borderline and the malignant ones and they mostly occurred in the 30 to 40 
years age group. Malignant surface epithelial ovarian tumours showed peak 
incidence in post-menopausal age group of 50 to 60years. As in the society 
even in this study, maximum cases presented at an advanced stage III. 
 
 With Immunohistochemical analysis, the percentage of EGFR and 
VEGF expression showed a significant increase in malignant compared to 
borderline tumours. Even among malignancies, EGFR and VEGF showed a 
significant correlation with tumour grade and FIGO stage. High grade and 
advanced stage tumours showed EGFR and VEGF overexpression compared to 
low grade and early stage carcinomas. 
 
 EGFR and VEGF both have diagnostic and therapeutic implications. 
Both markers were found to be independent prognostic factors in ovarian 
neoplasms. This is just a hospital based study that may not reflect the exact 
occurrence in the community as a whole. There is a wide arena of community 
based studies and research activities being carried out with these two markers - 
opening up newer dimensions and horizons in the ‘early diagnosis’ and 
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‘chemotherapeutic approaches’ with anti EGFR and VEGF antibodies in the 
battle against this ‘silent killer’ called ‘Cancer Ovary’. 
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ANNEXURE 1 
 
WHO CLASSIFICATION OF OVARIAN TUMORS 
 
TABLE 31.1 WHO Histological Classification of Tumors of the Ovary 
 
Surface epithelial–stromal tumors 
Serous tumors 
Malignant 
    Adenocarcinoma 
Borderline tumor 
Benign 
    Cystadenoma, adenofibroma, cystadenofibroma 
 
Mucinous tumors 
  Malignant 
    Adenocarcinoma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, cystadenofibroma 
  Mucinous cystic tumor with pseudomxoma peritonei 
Endometrioid tumors including variants with squamous differentiation 
  Malignant 
    Adenocarcinoma 
    Malignant mixed müllerian tumor (carcinosarcoma) 
    Endometrioid stromal sarcoma (low grade) 
    Undifferentiated ovarian sarcoma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, cystadenofibroma 
Clear cell tumors 
  Malignant 
    Adenocarcinofibroma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, cystadenofibroma 
Transitional cell tumors 
  Malignant 
    Transitional cell carcinoma (non-Brenner type) 
    Malignant Brenner tumor 
  Borderline 
  Benign 
    Brenner tumor 
Squamous cell tumors 
  Squamous cell carcinoma 
Mixed epithelial tumors (specify components) 
  Malignant 
  Borderline 
  Benign 
Undifferentiated and unclassified tumors 
  Undifferentiated carcinoma 
  Adenocarcinoma, not otherwise specified 
Sex-cord stromal tumors 
Granulosa-stromal cell tumors 
  Granulosa cell tumor group 
    Adult granulosa cell tumor 
    Juvenile granulosa cell tumor 
Thecoma-fibroma group 
  Thecoma, not otherwise specified 
    Typical 
    Luteinized 
  Fibroma 
  Cellular fibroma 
  Fibrosarcoma 
  Stromal tumor with minor sex cord elements 
  Sclerosing stromal tumor 
  Signet-ring stromal tumor 
  Unclassified (fibrothecoma) 
Sertoli-stromal cell tumors 
  Sertoli-Leydig cell tumor group 
    Well differentiated 
    Of intermediate differentiation 
      Variant with heterologous elements (specify type) 
    Poorly differentiated (sarcomatoid) 
      Variant with heterologous elements (specify type) 
    Retiform 
      Variant with heterologous elements (specify type) 
  Sertoli cell tumor 
  Stromal-Leydig cell tumor 
  Sex cord-stromal tumors of mixed or unclassified cell types 
  Sex cord tumor with annular tubules 
  Gynandroblastoma (specify components) 
  Sex cord-stromal tumor, unclassified 
Steroid cell tumors 
  Stromal luteoma 
  Leydig cell tumor group 
    Hilus cell tumor 
    Leydig cell tumor, nonhilar type 
    Leydig cell tumors, not otherwise specified 
  Steroid cell tumor, not otherwise specified 
    Well differentiated 
    Malignant 
 
Germ cell tumors 
Primitive germ cell tumors 
Dysgerminoma 
Yolk sac tumor 
Embryonal carcinoma 
Polyembryoma 
Nongestational choriocarcinoma 
Mixed germ cell tumor (specify components) 
Biphasic or triphasic teratoma 
Immature teratoma 
Mature teratoma 
  Solid 
  Cystic 
  Fetiform teratoma (homunculus) 
Monodermal teratoma and somatic-type tumors associated with dermoid cysts 
Thyroid tumor group 
  Struma ovarii 
    Benign 
    Malignant (specify type) 
Cardinoid group 
Neuroectodermal tumor group 
Carcinoma group 
Melanocytic group 
  Malignant melanoma 
  Melanocytic nevus 
Sarcoma group (specify type) 
Sebaceous tumor group 
Pituitary-type tumor group 
Retinal anlage tumor group 
Others 
Germ cell sex cord-stromal tumors 
Gonadoblastoma 
  Variant with malignant germ cell tumor 
Mixed germ cell-sex cord-stromal tumor 
  Variant with malignant germ cell tumor 
Tumors of the rete ovarii 
Adenocarcinoma 
Adenoma 
Cystadenoma 
Cystadenofibroma 
Miscellaneous tumors 
Small cell carcinoma, hypercalcemic type 
Small cell carcinoma, pulmonary type 
Large cell neuroendocrine carcinoma 
Hepatoid carcinoma 
Primary ovarian mesothelioma 
Wilms tumor 
Gestational choriocarcinoma 
Hydatidiform mole 
Adenoid cystic carcinoma 
Basal cell tumor 
Ovarian 
Wolffian tumor 
Paraganglioma 
Myxoma 
Soft tissue tumors not specific to the ovary 
Others 
Tumor like conditions 
Luteoma of pregnancy 
Stromal hyperthecosis 
Stromal hyperplasia 
Fibromatosis 
Massive ovarian edema 
Others 
 
Lymphoid and hematopoetic tumors 
Malignant lymphoma (specify type) 
Leukemia (specify type) 
Plasmacytoma 
 
Secondary tumors 
 From: Tavassoli FA, Devilee P, eds. World Health Organization 
Classification of Tumours. Pathology and Genetics. Tumours of the Breast 
and Female Genital Organs. Lyon: IARC Press; 2003. Used with permission. 
 
Annexure 2 
STAGING OF OVARIAN CARCINOMA 
 
 
 
  
 
 
 
 
 
ANNEXURE  3 
 
GRADING OF OVARIAN CANCER 
As per AJCC – American Joint Committee on Cancer. 
Gx – Grade cannot be evaluated 
GB – Borderline cancerous 
G1 – The tumour is well differentiated 
G2 – The tumour is moderately differentiated 
G3 to G4 – The tumour is poorly differentiated or undifferentiated 
 
 
 
  
  
 
ANNEXURE 4 
 
Scoring system for the ImmunoHistoChemical marker 
EGFR and VEGF  (Cytoplasmic and  / or Membranous  Staining) 
Percentage: 
O/negative – positive staining in <5% of cells 
1+    positive staining in 5 to 25% of tumour cells 
2+    positive staining in> 25 to <50% of tumour cells 
3+     positive staining in >50% of tumour cells 
Intensity of staining graded as weak (+), moderate (2+) and strong (3+). 
 
 
 
INFORMATION SHEET 
 
Title : Expression of IHC markers EGFR (Epidermal Growth Factor 
Receptor) and VEGF (Vascular Endothelial Growth Factor) in epithelial 
ovarian neoplasms 
 
 Your specimen has been accepted. 
 We are conducting a study on Epithelial ovarian neoplasms among 
patients attending Government Kasthurba Gandhi Hospital for 
women, Chennai and for that your specimen may be valuable to us. 
 The purpose of this study is to study the expression of Vascular 
endothelial growth factor (VEGF) and epidermal growth factor 
receptor (EGFR) in epithelial ovarian neoplasms which could thence 
be used as therapeutic targets in future.  
 We are selecting certain cases and if your specimen is found 
eligible, we may be using your specimen to perform extra tests and 
special studies which in any way do not affect your final report or 
management. 
 The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable 
information will be shared. 
 Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are 
otherwise entitled. 
 The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found 
abnormal which may aid in the management or treatment. 
 
 
 
Signature of investigator    Signature of participant 
 
 
Date:  
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C¢u Bµõ´a]°À £[÷PØ£x u[PÐøh¯ Â¸¨£zvß ÷£¶À uõß 
C¸UQÓx. ÷©¾® }[PÒ G¢÷{µ¬® C¢u Bµõ´a]°À C¸¢x 
¤ßÁõ[P»õ® Gß£øu²® öu¶ÂzxU öPõÒQ÷Óõ®. 
 C¢u ]Ó¨¦¨ £¶÷\õuøÚPÎß ¬iÄPøÍ Bµõ´a]°ß ÷£õx 
AÀ»x Bµõ´a]°ß ¬iÂß ÷£õx u[PÐUS AÔÂ¨÷£õ® Gß£øu²® 
öu¶ÂzxU öPõÒQ÷Óõ®. 
C¢u B´øÁ £ØÔ¯ \¢÷uP[PÐUS öuõhº¦ öPõÒÍ ÷Ási¯Áº :  
©¸. D.Ps©o. ö\À : 9444491720 
 
 
 
£[÷PØ£õÍº øPö¯õ¨£®................. Ch® :............. ÷uv :...................... 
£[÷PØ£õÍº ö£¯º ©ØÖ® Â»õ\® ....................................................... 
Bµõ´a]¯õÍº øPö¯õ¨£®...................... Ch® :............. ÷uv :................ 
INFORMED CONSENT FORM 
Title of the study : “Expression of IHC markers EGFR (Epidermal Growth Factor 
Receptor) and VEGF (Vascular Endothelial Growth Factor) in epithelial ovarian neoplasms” 
Name of the Participant :  
Name of the Principal (Co-Investigator) : 
Name of the Institution : Madras Medical College 
Name and address of the sponsor / agency (ies) (if any) : 
 
Documentation of the informed consent 
 
I _____________________________ have read the information in this form (or it has been 
read to me). I was free to ask any questions and they have been answered. I am over 18 
years of age and, exercising my free power of choice, hereby give my consent to be included 
as a participant in the study on “EXPRESSION OF IHC MARKERS EGFR (EPIDERMAL GROWTH 
FACTOR RECEPTOR) AND VEGF (VASCULAR ENDOTHELIAL GROWTH FACTOR) IN EPITHELIAL 
OVARIAN NEOPLASMS”. 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study in which the resected soft tissue 
tumors will be subjected to immunohistochemistry and histopathological examination. 
4. I have been explained about my rights and responsibilities by the investigator. I have the 
right to withdraw from the study at any time. 
5. I have been informed the investigator of all the treatments I am taking or have taken in 
the past ________ months including any native (alternative) treatment. 
6. I hereby give permission to the investigators to release the information obtained from 
me as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC. I understand that they are publicly presented. 
7. I have understand that my identity will be kept confidential if my data are publicly 
presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the investigator. By 
signing this consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, I will be given a copy of this consent 
document. 
 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant 
incompetent) 
Name _________________________ Signature____________ Date______________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name _________________________ Signature____________ Date______________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature____________ Date______________ 
Bµõ´a] J¨¦uÀ Piu® 
 
Bµõ´a] uø»¨¦  :   P¸¬møh PmiPøÍ £ØÔ¯ B´Ä. 
 
 ö\ßøÚ ©¸zxÁU PÀ¿¶ ÷{õ´SÔ°¯À xøÓ°À  £°¾® 
¬xPø» ©¸zxÁº D. Ps©o, AÁºPÒ ÷©ØöPõÒÐ® C¢u B´ÂÀ 
£[SöPõÒÍ ............................................................ BQ¯ {õß ¬Ê ©Úxhß 
\®©vUQ÷Óß. 
 
 C¢u Bµõ´a]°ß ÂÁµ[PÐ® Auß ÷{õUP[PÐ® ¬Êø©¯õP 
GÚUS öuÎÁõP ÂÍUP¨£mhx. 
 
 GÚUS ÂÍUP¨£mh Âå¯[PøÍ {õß ¦¶¢x öPõsk {õß GÚx 
\®©uzøuz öu¶ÂUQ÷Óß. 
 
 C¢u Bµõ´a]°À ¤Ó¶ß |º¨£¢uªßÔ Gß ö\õ¢u Â¸¨£zvß 
÷£¶À uõß £[S ö£ÖQ÷Óß ©ØÖ® {õß C¢u Bµõ´a]°¼¸¢x 
G¢÷{µ¬® ¤ßÁõ[P»õ® Gß£øu²® AuÚõÀ G¢u £õv¨¦® HØ£hõx 
Gß£øu²® {õß ¦¶¢x öPõs÷hß. 
 
 {õß P¸¬møh Pmi ÷{õ´PÒ SÔzu C¢u Bµõ´a]°ß 
ÂÁµ[PøÍU öPõsh uPÁÀ uõøÍ¨ ö£ØÖU öPõs÷hß. 
 
 {õß GßÝøh¯ _¯|øÚÄhß ©ØÖ® ¬Ê _u¢vµzxhß C¢u 
©¸zxÁ Bµõ´a]°À GßøÚ ÷\ºzxU öPõÒÍ \®©vUQ÷Óß. 
 
 GÚUS AÖøÁ ]Qaø\ ö\´¯¨£mk ÷{õ´USÔ°¯À xøÓ°À 
\øu¨ £¶÷\õuøÚUS £¯ß£mh ö©ÊSUPmiPøÍ øÁzx Bµõ´a] 
©ØÖ® ]Ó¨¦¨ £¶÷\õuøÚ ö\´¯x öPõÒÍ \®©u® öu¶ÂUQ÷Óß. 
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Master Chart 
  
MASTER CHART 
 
Sl NO BIOPSY NO AGE PROCEDURE DONE HISTOPATHOLOGICAL TYPE GRADE STAGE EGFR VEGF 
1 1691/12 40 Ovarian Cystectomy Serous cystadenoma     2 1692/12 40 TAH With BSO Serous cystadenofibroma     3 1533/12 20 TAH With BSO mucinous cystadenoma     4 1779/12 23 TAH With BSO mucinous cystadenoma     5 1884/12 40 TAH With BSO mucinous cystadenoma     6 1912/12 21 Cystectomy mucinous cystadenoma     7 1968/12 40 Staging Laprotomy mucinous cystadenoma     8 2431/12 32 Cystectomy Serous cystadenoma     9 2490/12 55 TAH With BSO mucinous cystadenoma     10 827/12 40 TAH With BSO mucinous cystadenoma     11 705/12 20 TAH With BSO mucinous cystadenoma     12 1095/12 32 TAH With BSO Serous cystadenoma     13 462/12 40 TAH With BSO mucinous cystadenoma     14 990/12 21 Cystectomy Serous cystadenofibroma     15 555/12 20 Cystectomy Papillary Serous Cystadenoma     16 567/12 51 TAH With BSO Papillary Serous Cystadenoma     17 608/12 40 TAH With BSO mucinous cystadenoma     18 1018/12 27 Cystectomy mucinous cystadenoma     19 1090/12 40 TAH With BSO mucinous cystadenoma     20 513/13 68 Staging Laprotomy Papillary Serous Cystadenocarcinoma 3 III C 3+ 3+ 
21 2559/13 45 Staging Laprotomy Papillary Serous Cystadenocarcinoma 2 III B 2+ 3+ 
22 184/13 45 Staging Laprotomy Papillary Serous Cystadenocarcinoma 3 III C 3+ 3+ 
23 903/13 48 Staging Laprotomy Papillary Serous Cystadenocarcinoma 3 III C 3+ 3+ 
24 1105/13 58 Staging Laprotomy Endometrioid adenocarcinoma of ovary 2 II A 3+ 3+ 
25 976/13 63 Staging Laprotomy Mucinous adenocarcinoma ovary 2 II A 3+ 3+ 
26 2209/13 61 Staging Laprotomy Clear cell carcinoma ovary 3 III C 3+ 3+ 
27 305/13 58 Staging Laprotomy Atypical proliferating serous tumor 1  2+ 2+ 28 405/13 54 Staging Laprotomy Atypical proliferating serous tumor 1  2+ 2+ 29 321/13 26 Cystectomy Mucinous cystadenofibroma     30 668/13 39 TAH With BSO Pap serous cystadenofibroma     31 750/13 51 TAH With BSO Pap serous cystadenofibroma     32 1024/13 26 Cystectomy Mucinous cystadenoma     33 884/13 50 Staging Laprotomy Serous cystadenofibroma     34 1000/13 40 Staging Laprotomy Serous cystadenofibroma     
 Sl NO BIOPSY NO AGE PROCEDURE DONE HISTOPATHOLOGICAL TYPE GRADE STAGE EGFR VEGF 
35 1063/13 28 Cystectomy mucinous cystadenoma     36 1155/13 54 TAH With BSO mucinous cystadenoma     37 1300/13 38 Staging Laprotomy mucinous cystadenoma     38 1478/13 50 TAH With BSO Papillary Serous Cystadenofibroma     39 1919/13 43 TAH With BSO mucinous cystadenoma     40 1988/13 46 TAH With BSO mucinous cystadenoma     41 2033/13 40 TAH With BSO Papillary Serous Cystadenofibroma     42 2116/13 38 TAH With BSO Papillary Serous Cystadenofibroma     43 2232/13 36 TAH With BSO mucinous cystadenoma     44 35/13 34 TAH With BSO Papillary Serous Cystadenofibroma     
45 104/14 50 Staging Laprotomy Micropapillary Serous Cystadenocarcinoma 3 III B 3+ 3+ 
46 700/14 58 Staging Laprotomy Papillary Serous Cystadenocarcinoma 3 III B 3+ 3+ 
47 2560/14 49 Staging Laprotomy Papillary Serous Cystadenocarcinoma 2 II A Neg Neg 
48 205/14 42 Staging Laprotomy Endometrioid adenocarcinoma of ovary 2 II A 3+ 3+ 
49 305/14 50 Staging Laprotomy Endometrioid adenocarcinoma of ovary 2 II A Neg Neg 
50 92/14 45 Staging Laprotomy Endometrioid adenocarcinoma of ovary 3 II A 3+ 3+ 
51 342/14 76 Staging Laprotomy Mucinous adenocarcinoma ovary 3 III B 3+ 3+ 
52 428/14 45 Staging Laprotomy Mucinous adenocarcinoma ovary 1 II A Neg 2+ 
53 1088/14 53 Staging Laprotomy Clear cell carcinoma ovary 3 III C 3+ 3+ 
54 404/14 52 Staging Laprotomy Adenosquamous carcinoma ovary 3 III C Neg Neg 
55 1028/14 48 Staging Laprotomy Atypical proliferating mucinous tumor 1  Neg 1+ 56 3143/14 27 TAH With BSO Mucinous cystadenoma     57 3293/14 45 TAH With BSO Serous cystadenoma     58 3819/14 35 TAH With BSO mucinous cystadenoma     59 3943/14 31 TAH With BSO mucinous cystadenoma     60 1324/14 31 Ovarian Cystectomy serous cystadenoma     61 2358/14 32 Ovarian Cystectomy Pap serous cystadenofibroma     62 2521/14 33 TAH With BSO Serous cystadenoma     63 2458/14 33 TAH With BSO mucinous cystadenoma     64 2624/14 34 TAH With BSO mucinous cystadenoma     65 2636/14 45 TAH With BSO Serous cystadenofibroma     66 85/14 32 TAH With BSO Serous cystadenofibroma     67 222/14 35 TAH With BSO mucinous cystadenofibroma     68 750/15 46 Staging Laprotomy Papillary Serous Cystadenocarcinoma 2 II A 2+ 3+ 
69 1842/15 53 Staging Laprotomy Papillary Serous Cystadenocarcinoma 2 II B 2+ 2+ 
70 3249/15 58 Staging Laprotomy Endometrioid adenocarcinoma ovary 3 III C 3+ 3+ 
71 3160/15 66 Staging Laprotomy Endometrioid adenocarcinoma of ovary 3 III B 3+ 3+ 
72 93/15 60 Staging Laprotomy Endometrioid adenocarcinoma of ovary 2 II A 2+ 2+ 
 Sl NO BIOPSY NO AGE PROCEDURE DONE HISTOPATHOLOGICAL TYPE GRADE STAGE EGFR VEGF 
73 877/15 70 Staging Laprotomy Mucinous adenocarcinoma ovary 1 II B Neg Neg 
74 254/15 70 Staging Laprotomy Clear cell carcinoma ovary 3 III C 3+ 3+ 
75 1974/15 60 Staging Laprotomy Clear cell carcinoma ovary 3 III B 3+ 3+ 
76 610/15 45 Staging Laprotomy Atypical proliferating mucinous tumor 1  Neg Neg 77 950/15 22 Lap Cystectomy Papillary Serous Cystadenofibroma     78 1109/15 57 Staging Laprotomy Benign Brenner     79 673/15 27 Cystectomy Benign mucinous cystadenoma     80 715/15 41 TAH With BSO Benign serous cystadenoma     81 743/15 40 TAH With BSO Benign mucinous cystadenoma     82 744/15 54 TAM With B81 Benign mucinous cystadenoma     83 849/15 24 Ovarian Cystectomy Benign serous cystadenoma     
84 867/15 48 TAH With BSO Benign Papillary Serous Cystadenofibroma     
85 52/15 36 TAH With BSO Pap serous cystadenofibroma     86 137/15 48 Staging Laprotomy serous cystadenoma     87 138/15 50 Staging Laprotomy serous cystadenoma     88 381/15 27 Ovarian Cystectomy mucinous cystadenoma     89 431/15 33 TAH With BSO Benign serous cystadenoma     90 438/15 26 Ovarian Cystectomy papillary serous cystadenofibroma     91 955/1 67 Staging Laprotomy Endometrioid adenocarcinoma of ovary 2 II A 2+ 2+ 
92 942/15 37 TAH With BSO mucinous cystadenoma      
 
 
KEY TO MASTER CHART 
 
TAH with BSO  - Total Abdominal Hysterectomy with Bilateral Salpingo Oophorectomy 
EGFR   -  Epidermal Growth Factor Receptor 
VEGF   - Vascular Endothelial Growth Factor  
Neg   - Negative 
